Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Alert: The Harvard Catalyst website will be unavailable due to system maintenance from Friday (02/24) 10pm to Saturday (02/25) 1pm.
Keywords
Last Name
Institution

profilePatrick Yung Chih Wen, M.D.

TitleProfessor of Neurology
InstitutionBrigham and Women's Hospital
DepartmentNeurology
AddressDana Farber Cancer Institute
G4200
44 Binney St
Boston MA 02115
Phone617/632-2166
Fax617/632-4773
vCardDownload vCard (login for email)

Collapse Mentoring 
Collapse completed student projects
Retrospective study of using carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab
Full Time/Year Long, 06/04/12 - 05/31/13
Imaging Patterns Predict Survival in Recurrent Glioblastoma Patients Treated With Bevacizumab
Summer, 02/01/15 - 01/01/16
Predicting Isocitrate Dehydrogenase Mutation Status and Survival Outcome in High-Grade Gliomas with Multimodality Imaging Markers
Spanish/Summer/Continuation, 11/01/14 - 12/18/15
Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases as Serum Biomarker for Glioma
International, 06/21/10 - 08/06/10

Collapse Research 
Collapse research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
P50CA165962     (BATCHELOR, TRACY T)Sep 19, 2013 - Jul 31, 2018
NIH/NCI
SPORE: Targeted Therapies for Glioma
Role: Co-Principal Investigator

U01CA062407     (WEN, PATRICK Y)Apr 8, 1994 - Dec 31, 2008
NIH/NCI
Therapeutics Studies of Primary CNS Malignancies
Role: Principal Investigator

K11CA001492     (WEN, PATRICK Y)Jul 1, 1990 - Jun 30, 1995
NIH/NCI
IMMUNOTHERAPY FOR MALIGNANT GLIOMAS
Role: Principal Investigator

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Cavaliere R, Wen PY, Schiff D. Novel Therapies in Brain Tumors. Neurol Clin. 2050.
  2. Schiff D, Kesari S, Wen PY, editors. Cancer Neurology in Clinical Practice. 2050.
  3. Wen PY, Schiff D. Neurologic Complications of Prostate Cancer. Kantoff PW, Carroll P, D'Amico A, editors. Prostate Cancer. 2050.
  4. Fitzsimmons A, Wen PY. Neurologic complications of chemotherpay. Newton H, Malkin M, editors. Neurologic complications of systemic cancer and antineoplastic therapy. 2050.
  5. Savani A, Schiff D, Wen PY. Nervous System Metastases. Bradley W, daroff R, Fenichel G, Jankovic J, editors. Neurology in Clinical Practice. 2050.
  6. Monje M, Wen PY. Neurological Complications of Oncology Therapy. Newton h, Jolesz F, editors. Handbook fo neuro-Oncology Neuro-Imaging. 2050.
  7. Dietrich J, Wen PY. Neurologic Complications of Chemotherapy. Schiff D, Kesari S, Wen PY, editors. Cancer Neurology in Clinical Practice. 2050.
  8. Chi A, Norden A, Wen PY. Antiangiogenic Therapy for malignant Gliomas. Expert Rev in AntiCancer Therapy. 2050.
  9. Wen PY. Cancer Neurology. Samuels MA, editor. Neurology for the Practicing Physician. 2050.
  10. Norden A, Wen PY. Targeted Molecular Therapies for Meningiomas. Nurosurg Focus. 2050.
  11. Drappatz J, Wen PY. Therapy for Peritumoral Edema in High Grade Gliomas. Rivista Medica. 2050.
  12. Quant E, Wen PY. Neurologic complications of Bone Marrow Transplantation. Schiff D, Kesari S, Wen PY, editors. Cancer Neurology in Clinical Practice. 2050.
  13. Wen PY, Schiff D, editors. Brain Tumors in Adults. Neurologic Clinics. 2050.
  14. Schiff D, Wen PY. CNS toxicities from cancer therapy. Neurologic Clinics. 2050.
  15. Chi A, Wen PY. Inhibiting Angiogenesis in Malignant Gliomas. Griswold W, Soffieti R, editors. handbook of Clinical Neurology: Neuro-Oncology. 2050.
  16. Monje M, Wen PY. Neurological Complications of Oncological therapy. Turner CD, Goldman S, editors. Late Effects of Treatment for Brain Tumors. 2050.
  17. Fitzsimmons A, Wen PY. Tumors of the Spinal Cord. Neurology: Basic and Clinical Neurosciences. 2050.
  18. Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 Jan 23. PMID: 28116649.
    View in: PubMed
  19. Ellingson BM, Wen PY, Cloughesy TF. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics. 2017 Jan 20. PMID: 28108885.
    View in: PubMed
  20. Sun Y, Wen P, Yoon Y, Liu G, Steger M, Pfeiffer LN, West K, Snoke DW, Nelson KA. Bose-Einstein Condensation of Long-Lifetime Polaritons in Thermal Equilibrium. Phys Rev Lett. 2017 Jan 06; 118(1):016602. PMID: 28106443.
    View in: PubMed
  21. Wen PY. Message from the Editor-in-Chief. Neuro Oncol. 2017 Jan; 19(1):1. PMID: 28031379.
    View in: PubMed
  22. Ly KI, Wen PY. Clinical Relevance of Steroid Use in Neuro-Oncology. Curr Neurol Neurosci Rep. 2017 Jan; 17(1):5. PMID: 28138871.
    View in: PubMed
  23. Chamberlain M, Junck L, Brandsma D, Soffietti R, Rudà R, Raizer J, Boogerd W, Taillibert S, Groves MD, Rhun EL, Walker J, van den Bent M, Wen PY, Jaeckle KA. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol. 2016 Dec 29. PMID: 28039364.
    View in: PubMed
  24. Kalpathy-Cramer J, Chandra V, Da X, Ou Y, Emblem KE, Muzikansky A, Cai X, Douw L, Evans JG, Dietrich J, Chi AS, Wen PY, Stufflebeam S, Rosen B, Duda DG, Jain RK, Batchelor TT, Gerstner ER. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. J Neurooncol. 2016 Nov 16. PMID: 27853960.
    View in: PubMed
  25. Miller JJ, Wen PY. Emerging targeted therapies for glioma. Expert Opin Emerg Drugs. 2016 Dec; 21(4):441-452. PMID: 27809598.
    View in: PubMed
  26. Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2016 Nov; 29(6):627-642. PMID: 27615400.
    View in: PubMed
  27. Stevens MM, Maire CL, Chou N, Murakami MA, Knoff DS, Kikuchi Y, Kimmerling RJ, Liu H, Haidar S, Calistri NL, Cermak N, Olcum S, Cordero NA, Idbaih A, Wen PY, Weinstock DM, Ligon KL, Manalis SR. Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol. 2016 Nov; 34(11):1161-1167. PMID: 27723727.
    View in: PubMed
  28. Avila EK, Chamberlain M, Schiff D, Reijneveld JC, Armstrong TS, Ruda R, Wen PY, Weller M, Koekkoek JA, Mittal S, Arakawa Y, Choucair A, Gonzalez-Martinez J, MacDonald DR, Nishikawa R, Shah A, Vecht CJ, Warren P, van den Bent MJ, DeAngelis LM. Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro Oncol. 2017 Jan; 19(1):12-21. PMID: 27651472.
    View in: PubMed
  29. Huang RY, Wen PY. Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints. Magn Reson Imaging Clin N Am. 2016 Nov; 24(4):705-718. PMID: 27742111.
    View in: PubMed
  30. Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro Oncol. 2017 Jan; 19(1):89-98. PMID: 27580889.
    View in: PubMed
  31. O'Neill AF, Qin L, Wen PY, de Groot JF, Van den Abbeele AD, Yap JT. Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol. 2016 Dec; 130(3):495-503. PMID: 27576699.
    View in: PubMed
  32. Lee EQ, Wen PY. Corticosteroids for peritumoral edema: time to overcome our addiction? Neuro Oncol. 2016 Sep; 18(9):1191-2. PMID: 27530501.
    View in: PubMed
  33. Arvold ND, Lee EQ, Mehta MP, Margolin K, Alexander BM, Lin NU, Anders CK, Soffietti R, Camidge DR, Vogelbaum MA, Dunn IF, Wen PY. Updates in the management of brain metastases. Neuro Oncol. 2016 Aug; 18(8):1043-65. PMID: 27382120.
    View in: PubMed
  34. Eisele SC, Wen PY, Lee EQ. Assessment of Brain Tumor Response: RANO and Its Offspring. Curr Treat Options Oncol. 2016 Jul; 17(7):35. PMID: 27262709.
    View in: PubMed
  35. Hathout L, Patel V, Wen P. A 3-dimensional DTI MRI-based model of GBM growth and response to radiation therapy. Int J Oncol. 2016 Sep; 49(3):1081-7. PMID: 27572745.
    View in: PubMed
  36. Zhang B, Chang K, Ramkissoon S, Tanguturi S, Bi WL, Reardon DA, Ligon KL, Alexander BM, Wen PY, Huang RY. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol. 2017 Jan; 19(1):109-117. PMID: 27353503.
    View in: PubMed
  37. Miller MB, Bi WL, Ramkissoon LA, Kang YJ, Abedalthagafi M, Knoff DS, Agarwalla PK, Wen PY, Reardon DA, Alexander BM, Laws ER, Dunn IF, Beroukhim R, Ligon KL, Ramkissoon SH. MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget. 2016 Jun 14; 7(24):37054-37063. PMID: 27175596.
    View in: PubMed
  38. Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discov. 2016 Jul; 6(7):740-53. PMID: 27217383.
    View in: PubMed
  39. Chang K, Zhang B, Guo X, Zong M, Rahman R, Sanchez D, Winder N, Reardon DA, Zhao B, Wen PY, Huang RY. Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. Neuro Oncol. 2016 Dec; 18(12):1680-1687. PMID: 27257279.
    View in: PubMed
  40. Cabrera AR, Kirkpatrick JP, Fiveash JB, Shih HA, Koay EJ, Lutz S, Petit J, Chao ST, Brown PD, Vogelbaum M, Reardon DA, Chakravarti A, Wen PY, Chang E. Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):217-25. PMID: 27211230.
    View in: PubMed
  41. Helfer JL, Wen PY, Blakeley J, Gilbert MR, Armstrong TS. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD). Neuro Oncol. 2016 Mar; 18 Suppl 2:ii26-ii36. PMID: 26989130.
    View in: PubMed
  42. Wang GL, Liu Y, Qiu P, Zhou SF, Xu LF, Wen P, Wen JB, Xiao XZ. Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis. Eur Rev Med Pharmacol Sci. 2016 Mar; 20(5):866-72. PMID: 27010143.
    View in: PubMed
  43. Lee EQ, Muzikansky A, Drappatz J, Kesari S, Wong ET, Fadul CE, Reardon DA, Norden AD, Nayak L, Rinne ML, Alexander BM, Arvold ND, Doherty L, Stefanik J, LaFrankie D, Ruland SF, Pulverenti J, Smith KH, Gaffey SC, Hammond S, Wen PY. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro Oncol. 2016 Jun; 18(6):849-54. PMID: 26902850.
    View in: PubMed
  44. Curry WT, Gorrepati R, Piesche M, Sasada T, Agarwalla P, Jones PS, Gerstner ER, Golby AJ, Batchelor TT, Wen PY, Mihm MC, Dranoff G. Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clin Cancer Res. 2016 Jun 15; 22(12):2885-96. PMID: 26873960.
    View in: PubMed
  45. Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, Listewnik ML, Dias-Santagata D, Thorner AR, Van Hummelen P, Brastianos PK, Reardon DA, Wen PY, Al-Mefty O, Ramkissoon SH, Folkerth RD, Ligon KL, Ligon AH, Alexander BM, Dunn IF, Beroukhim R, Santagata S. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 May; 18(5):649-55. PMID: 26826201.
    View in: PubMed
  46. Diamandis P, Ferrer-Luna R, Huang RY, Folkerth RD, Ligon AH, Wen PY, Beroukhim R, Ligon KL, Ramkissoon SH. Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. Diagn Pathol. 2016 Jan 27; 11:13. PMID: 26817999.
    View in: PubMed
  47. Wen PY, Reardon DA. Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 2016 Feb; 12(2):69-70. PMID: 26782337.
    View in: PubMed
  48. Wen PY. Message from the Editor-in-Chief. Neuro Oncol. 2016 Jan; 18(1):1. PMID: 26667135.
    View in: PubMed
  49. Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen PY. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer. 2016 Feb 15; 122(4):582-7. PMID: 26588662.
    View in: PubMed
  50. Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35. PMID: 26546453.
    View in: PubMed
  51. Levin VA, Tonge PJ, Gallo JM, Birtwistle MR, Dar AC, Iavarone A, Paddison PJ, Heffron TP, Elmquist WF, Lachowicz JE, Johnson TW, White FM, Sul J, Smith QR, Shen W, Sarkaria JN, Samala R, Wen PY, Berry DA, Petter RC. CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro Oncol. 2015 Nov; 17 Suppl 6:vi1-26. PMID: 26403167; PMCID: PMC4581696 [Available on 11/01/16].
  52. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov; 16(15):e534-42. PMID: 26545842; PMCID: PMC4638131 [Available on 11/01/16].
  53. Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2016 Feb 01; 22(3):575-81. PMID: 26490307.
    View in: PubMed
  54. Verreault M, Schmitt C, Goldwirt L, Pelton K, Haidar S, Levasseur C, Guehennec J, Knoff D, Labussière M, Marie Y, Ligon AH, Mokhtari K, Hoang-Xuan K, Sanson M, Alexander BM, Wen PY, Delattre JY, Ligon KL, Idbaih A. Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clin Cancer Res. 2016 Mar 01; 22(5):1185-96. PMID: 26482041.
    View in: PubMed
  55. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016 Apr; 18(4):557-64. PMID: 26449250.
    View in: PubMed
  56. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Lawson R, Loeffler JS, Lovely MP, Moots PL, Mrugala MM, Newton HB, Parney I, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tran D, Tran N, Vrionis FD, Weiss S, Wen PY, McMillian N, Engh AM. Central Nervous System Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015 Oct; 13(10):1191-202. PMID: 26483059.
    View in: PubMed
  57. Wen PY, Norden AD. Author response. Neurology. 2015 Sep 22; 85(12):1090. PMID: 26645061.
    View in: PubMed
  58. Chamberlain MC. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Sep 22; 85(12):1090. PMID: 26391415.
    View in: PubMed
  59. Aizer AA, Abedalthagafi M, Bi WL, Horvath MC, Arvold ND, Al-Mefty O, Lee EQ, Nayak L, Rinne ML, Norden AD, Reardon DA, Wen PY, Ligon KL, Ligon AH, Beroukhim R, Dunn IF, Santagata S, Alexander BM. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74. PMID: 26323607.
    View in: PubMed
  60. Nayak L, DeAngelis LM, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas JR, Peereboom DM, Rosenfeld SS, Muzikansky A, Zheng M, Urban P, Abrey LE, Omuro A, Wen PY. Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer. Cancer. 2015 Dec 1; 121(23):4165-72. PMID: 26308485.
    View in: PubMed
  61. Aizer AA, Bi WL, Kandola MS, Lee EQ, Nayak L, Rinne ML, Norden AD, Beroukhim R, Reardon DA, Wen PY, Al-Mefty O, Arvold ND, Dunn IF, Alexander BM. Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015 Dec 15; 121(24):4376-81. PMID: 26308667.
    View in: PubMed
  62. Gounder MM, Nayak L, Sahebjam S, Muzikansky A, Sanchez AJ, Desideri S, Ye X, Ivy SP, Nabors LB, Prados M, Grossman S, DeAngelis LM, Wen PY. Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. J Clin Oncol. 2015 Oct 1; 33(28):3186-92. PMID: 26282642.
    View in: PubMed
  63. Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015 Sep; 17(9):1188-98. PMID: 26250565; PMCID: PMC4588759 [Available on 09/01/16].
  64. Shankar GM, Francis JM, Rinne ML, Ramkissoon SH, Huang FW, Venteicher AS, Akama-Garren EH, Kang YJ, Lelic N, Kim JC, Brown LE, Charbonneau SK, Golby AJ, Sekhar Pedamallu C, Hoang MP, Sullivan RJ, Cherniack AD, Garraway LA, Stemmer-Rachamimov A, Reardon DA, Wen PY, Brastianos PK, Curry WT, Barker FG, Hahn WC, Nahed BV, Ligon KL, Louis DN, Cahill DP, Meyerson M. Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7. PMID: 26181761.
    View in: PubMed
  65. Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R, Reifenberger G. Glioma. Nat Rev Dis Primers. 2015 07 16; 1:15017. PMID: 27188790.
    View in: PubMed
  66. Wen PY. Controversies in neuro-oncology: role of whole-brain radiation therapy in the treatment of newly diagnosed brain metastases. Neuro Oncol. 2015 Jul; 17(7):915. PMID: 26092876.
    View in: PubMed
  67. Aizer AA, Du R, Wen PY, Arvold ND. Radiotherapy and death from cerebrovascular disease in patients with primary brain tumors. J Neurooncol. 2015 Sep; 124(2):291-7. PMID: 26080799.
    View in: PubMed
  68. Rahman R, Catalano PJ, Reardon DA, Norden AD, Wen PY, Lee EQ, Nayak L, Beroukhim R, Dunn IF, Golby AJ, Johnson MD, Chiocca EA, Claus EB, Alexander BM, Arvold ND. Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. J Neurooncol. 2015 Aug; 124(1):137-46. PMID: 26033544.
    View in: PubMed
  69. Reardon DA, Ligon KL, Chiocca EA, Wen PY. One size should not fit all: advancing toward personalized glioblastoma therapy. Discov Med. 2015 Jun; 19(107):471-7. PMID: 26175405.
    View in: PubMed
  70. Jafari-Khouzani K, Emblem KE, Kalpathy-Cramer J, Bjørnerud A, Vangel MG, Gerstner ER, Schmainda KM, Paynabar K, Wu O, Wen PY, Batchelor T, Rosen B, Stufflebeam SM. Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients. Transl Oncol. 2015 Jun; 8(3):137-46. PMID: 26055170; PMCID: PMC4486737.
  71. Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EG, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wen PY. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015 Jun; 16(6):e270-8. PMID: 26065612.
    View in: PubMed
  72. Wen PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, Mohile N, Lager JJ, Laird AD, Tang J, Jiang J, Egile C, Cloughesy TF. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro Oncol. 2015 Sep; 17(9):1275-83. PMID: 26019185; PMCID: PMC4588757 [Available on 09/01/16].
  73. Gerstner ER, Ye X, Duda DG, Levine MA, Mikkelsen T, Kaley TJ, Olson JJ, Nabors BL, Ahluwalia MS, Wen PY, Jain RK, Batchelor TT, Grossman S. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1386-92. PMID: 26008604; PMCID: PMC4578584 [Available on 10/01/16].
  74. Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015 Aug; 17(8):1051-63. PMID: 25934816; PMCID: PMC4490873 [Available on 08/01/16].
  75. Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15; 21(16):3610-8. PMID: 25910950.
    View in: PubMed
  76. Ding R, Feng L, He L, Chen Y, Wen P, Fu Z, Lin C, Yang S, Deng X, Zeng J, Sun G. Peroxynitrite decomposition catalyst prevents matrix metalloproteinase-9 activation and neurovascular injury after hemoglobin injection into the caudate nucleus of rats. Neuroscience. 2015 Jun 25; 297:182-93. PMID: 25849612.
    View in: PubMed
  77. Bruna J, Wen PY. Patient management problem-preferred responses. Continuum (Minneap Minn). 2015 Apr; 21(2 Neuro-oncology):541-56. PMID: 25837914.
    View in: PubMed
  78. Arvold ND, Tanguturi SK, Aizer AA, Wen PY, Reardon DA, Lee EQ, Nayak L, Christianson LW, Horvath MC, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Alexander BM. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 1; 92(2):384-9. PMID: 25841623.
    View in: PubMed
  79. Bruna J, Wen PY. Patient management problem. Continuum (Minneap Minn). 2015 Apr; 21(2 Neuro-oncology):535-40. PMID: 25837913.
    View in: PubMed
  80. Rinne ML, Wen PY. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide. Oncology (Williston Park). 2015 Apr; 29(4):265, 275. PMID: 25952491.
    View in: PubMed
  81. Neagu MR, Huang RY, Reardon DA, Wen PY. How treatment monitoring is influencing treatment decisions in glioblastomas. Curr Treat Options Neurol. 2015 Apr; 17(4):343. PMID: 25749847.
    View in: PubMed
  82. Bergthold G, Bandopadhayay P, Hoshida Y, Ramkissoon S, Ramkissoon L, Rich B, Maire CL, Paolella BR, Schumacher SE, Tabak B, Ferrer-Luna R, Ozek M, Sav A, Santagata S, Wen PY, Goumnerova LC, Ligon AH, Stiles C, Segal R, Golub T, Grill J, Ligon KL, Chan JA, Kieran MW, Beroukhim R. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol. 2015 Nov; 17(11):1486-96. PMID: 25825052; PMCID: PMC4648300 [Available on 11/01/16].
  83. Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, Dubuc A, Brown L, Burns M, Cryan JB, Abedalthagafi M, Kang YJ, Schultz N, Reardon DA, Lee EQ, Rinne ML, Norden AD, Nayak L, Ruland S, Doherty LM, LaFrankie DC, Horvath M, Aizer AA, Russo A, Arvold ND, Claus EB, Al-Mefty O, Johnson MD, Golby AJ, Dunn IF, Chiocca EA, Trippa L, Santagata S, Folkerth RD, Kantoff P, Rollins BJ, Lindeman NI, Wen PY, Ligon AH, Beroukhim R, Alexander BM, Ligon KL. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55. PMID: 25754088; PMCID: PMC4578577 [Available on 10/01/16].
  84. Huang RY, Neagu MR, Reardon DA, Wen PY. Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Front Neurol. 2015; 6:33. PMID: 25755649; PMCID: PMC4337341.
  85. Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7. PMID: 25572329; PMCID: PMC4483124 [Available on 06/01/16].
  86. Trippa L, Wen PY, Parmigiani G, Berry DA, Alexander BM. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials. Neuro Oncol. 2015 Aug; 17(8):1106-13. PMID: 25568226; PMCID: PMC4490868 [Available on 08/01/16].
  87. Reardon DA, Wen PY. Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat Rev Clin Oncol. 2015 Feb; 12(2):69-70. PMID: 25560529.
    View in: PubMed
  88. Zhou L, Bondy SC, Jian L, Wen P, Yang F, Luo H, Li W, Zhou J. Tanshinone IIA attenuates the cerebral ischemic injury-induced increase in levels of GFAP and of caspases-3 and -8. Neuroscience. 2015 Mar 12; 288:105-11. PMID: 25575944.
    View in: PubMed
  89. Wen PY. Message from the Editor-in-Chief. Neuro Oncol. 2015 Jan; 17(1):1. PMID: 25538095; PMCID: PMC4483060 [Available on 01/01/16].
  90. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, Schiff D, Weber DC, Wen PY, Vogelbaum MA. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015 Jan; 122(1):4-23. PMID: 25343186.
    View in: PubMed
  91. Jordan JT, Wen PY. Novel chemotherapeutic approaches in adult high-grade gliomas. Cancer Treat Res. 2015; 163:117-42. PMID: 25468229.
    View in: PubMed
  92. Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6. PMID: 25527270; PMCID: PMC4335993 [Available on 01/20/16].
  93. Chheda MG, Wen PY, Hochberg FH, Chi AS, Drappatz J, Eichler AF, Yang D, Beroukhim R, Norden AD, Gerstner ER, Betensky RA, Batchelor TT. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. J Neurooncol. 2015 Feb; 121(3):627-34. PMID: 25503302; PMCID: PMC4324090 [Available on 02/01/16].
  94. Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP, Stemmer-Rachamimov A, Wen PY, Betensky RA, Giorgio DH, Snodgrass K, Randall AE, Batchelor TT, Chi AS. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol. 2015 Feb; 121(3):557-63. PMID: 25411098; PMCID: PMC4323868 [Available on 02/01/16].
  95. Gilbert MR, Armstrong TS, Pope WB, van den Bent MJ, Wen PY. Facing the future of brain tumor clinical research. Clin Cancer Res. 2014 Nov 15; 20(22):5591-600. PMID: 25398842.
    View in: PubMed
  96. Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Moots PL, Mrugala MM, Newton HB, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tran D, Tran N, Vrionis FD, Wen PY, McMillian NR, Ho M. Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Nov; 12(11):1517-23. PMID: 25361798; PMCID: PMC4337873.
  97. Barone A, Sengupta R, Warrington NM, Smith E, Wen PY, Brekken RA, Romagnoli B, Douglas G, Chevalier E, Bauer MP, Dembowsky K, Piwnica-Worms D, Rubin JB. Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma. Oncotarget. 2014 Oct 30; 5(20):9811-22. PMID: 25238146; PMCID: PMC4259439.
  98. Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment. Neuro Oncol. 2015 Apr; 17(4):488-504. PMID: 25358508; PMCID: PMC4483077 [Available on 04/01/16].
  99. Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, Smith KH, Gaffey SC, McCluskey C, Ligon KL, Reardon DA, Wen PY. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol. 2015 Jan; 121(2):297-302. PMID: 25338318.
    View in: PubMed
  100. Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF. Pros and cons of current brain tumor imaging. Neuro Oncol. 2014 Oct; 16 Suppl 7:vii2-11. PMID: 25313235; PMCID: PMC4195528.
  101. Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014 Oct; 16 Suppl 7:vii36-47. PMID: 25313237; PMCID: PMC4195530.
  102. Reardon DA, Wen PY, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol. 2014 Oct; 16 Suppl 8:viii7-13. PMID: 25342602; PMCID: PMC4207137.
  103. Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff DS, Schultz N, Abedalthagafi M, Brown L, Wen PY, Reardon DA, Dunn IF, Folkerth RD, Santagata S, Lindeman NI, Ligon AH, Beroukhim R, Hornick JL, Alexander BM, Ligon KL, Ramkissoon SH. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30; 5(18):8083-92. PMID: 25257301; PMCID: PMC4226668.
  104. Field KM, Jordan JT, Wen PY, Rosenthal MA, Reardon DA. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Cancer. 2015 Apr 1; 121(7):997-1007. PMID: 25263092.
    View in: PubMed
  105. Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, Fritsch EF, Curry WT, Sampson JH, Dranoff G. Immunotherapy advances for glioblastoma. Neuro Oncol. 2014 Nov; 16(11):1441-58. PMID: 25190673; PMCID: PMC4201077.
  106. Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8. PMID: 25165194; PMCID: PMC4288520 [Available on 02/01/16].
  107. Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan; 17(1):116-21. PMID: 25100872; PMCID: PMC4483051 [Available on 01/01/16].
  108. Lee EQ, Ruland S, LeBoeuf NR, Wen PY, Santagata S. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy. J Clin Oncol. 2016 Apr 1; 34(10):e87-9. PMID: 25092772.
    View in: PubMed
  109. Wen PY. Point/counterpoint: is there a role for radiotherapy in the treatment of primary CNS lymphoma? Neuro Oncol. 2014 Aug; 16(8):1032. PMID: 25024359; PMCID: PMC4096188.
  110. Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol. 2014 Nov; 16(11):1541-6. PMID: 24997140; PMCID: PMC4201067.
  111. Wen PY, Wen PY, Yung WK, Mellinghoff IK, Ramkissoon S, Alexander B, Rinne M, Colman H, Omuro AM, DeAngelis LM, Gilbert MR, DeGroot J, Cloughesy TF, Lee EQ, Nayak L, Chi AS, Batchelor T, Chang SM, Prados MD, Reardon DA, Ligon KL. Phase ii trial of the phosphatidyinositol-3 kinase (pi3k) inhibitor buparlisib (bkm120) in recurrent glioblastoma conducted by the ivy foundation early phase clinical trials consortium. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii47. PMID: 25165346.
    View in: PubMed
  112. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen B, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12. PMID: 25165209.
    View in: PubMed
  113. Rahman R, Hempfling K, Norden AD, Reardon DA, Nayak L, Rinne ML, Beroukhim R, Doherty L, Ruland S, Rai A, Rifenburg J, LaFrankie D, Alexander BM, Huang RY, Wen PY, Lee EQ. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro Oncol. 2014 Nov; 16(11):1523-9. PMID: 24958095; PMCID: PMC4201074.
  114. Liu W, Ye H, Tang B, Song Z, Sun Z, Wen P, Yang J. Profile of interdialytic ambulatory blood pressure in a cohort of Chinese patients. J Hum Hypertens. 2014 Nov; 28(11):677-83. PMID: 24919753.
    View in: PubMed
  115. Aizer AA, Arvold ND, Catalano P, Claus EB, Golby AJ, Johnson MD, Al-Mefty O, Wen PY, Reardon DA, Lee EQ, Nayak L, Rinne ML, Beroukhim R, Weiss SE, Ramkissoon SH, Abedalthagafi M, Santagata S, Dunn IF, Alexander BM. Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53. PMID: 24891451; PMCID: PMC4201070.
  116. Chamberlain M, Soffietti R, Raizer J, Rudà R, Brandsma D, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Junck L, van den Bent M, Wen PY, Jaeckle KA. Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol. 2014 Sep; 16(9):1176-85. PMID: 24867803; PMCID: PMC4136900.
  117. Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundan S, Wen PY, Huang RY. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol. 2014 Aug; 119(1):149-58. PMID: 24805151.
    View in: PubMed
  118. Akgoz A, Rahman R, You H, Qu J, Hamdan A, Seethamraju RT, Wen PY, Young GS. Spin-echo echo-planar perfusion prior to chemoradiation is a strong independent predictor of progression-free and overall survival in newly diagnosed glioblastoma. J Neurooncol. 2014 Aug; 119(1):111-9. PMID: 24792644.
    View in: PubMed
  119. Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN. The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014 Jul; 118(3):501-55. PMID: 24740194.
    View in: PubMed
  120. Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN, Ryken TC. The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2014 Jul; 118(3):557-99. PMID: 24740195.
    View in: PubMed
  121. Wen PY, Junck L. Bevacizumab for glioblastoma: what can we learn from patterns of progression? Neurology. 2014 May 13; 82(19):1670-1. PMID: 24727316.
    View in: PubMed
  122. Reardon DA, Wen PY. Targeted therapies: Further delineating bevacizumab's response spectrum. Nat Rev Clin Oncol. 2014 May; 11(5):243-4. PMID: 24710578.
    View in: PubMed
  123. Lee JW, Norden AD, Ligon KL, Golby AJ, Beroukhim R, Quackenbush J, Wells W, Oelschlager K, Maetzold D, Wen PY. Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: a gene expression imaging study. Epilepsy Res. 2014 Jul; 108(5):843-52. PMID: 24690158; PMCID: PMC4076930.
  124. Wen PY. Controversies in neuro-oncology: does valganciclovir have a role in the treatment of high-grade gliomas? Neuro Oncol. 2014 Mar; 16(3):329. PMID: 24523452; PMCID: PMC3922529.
  125. Wang TS, Lei W, Cui W, Wen P, Guo HF, Ding SG, Yang YP, Xu YQ, Lv SW, Zhu YL. A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer. Indian J Cancer. 2014 Mar; 51 Suppl 3:e95-8. PMID: 25818743.
    View in: PubMed
  126. Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, Wen P. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014 Jun; 16(6):829-40. PMID: 24500419; PMCID: PMC4022224.
  127. Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014 Apr; 16(4):567-78. PMID: 24470557; PMCID: PMC3956354.
  128. Wen PY. New editorial team for neuro-oncology. Neuro Oncol. 2014 Jan; 16(1):1. PMID: 24366972; PMCID: PMC3870844.
  129. Arrillaga-Romany I, Reardon DA, Wen PY. Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs. 2014 Feb; 23(2):199-210. PMID: 24320142.
    View in: PubMed
  130. Pinho MC, Polaskova P, Kalpathy-Cramer J, Jennings D, Emblem KE, Jain RK, Rosen BR, Wen PY, Sorensen AG, Batchelor TT, Gerstner ER. Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. Oncologist. 2014 Jan; 19(1):75-81. PMID: 24309981; PMCID: PMC3903059.
  131. Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, Yip S, Yen K, Costello JF, Chang S. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Neuro Oncol. 2014 Jan; 16(2):173-8. PMID: 24305708; PMCID: PMC3895389.
  132. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64. PMID: 24190997; PMCID: PMC3839699.
  133. Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, Kalkanis SN, Barani IJ, Baumert BG, Gaspar LE, Hodi FS, Macdonald DR, Wen PY. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e407-16. PMID: 23993385.
    View in: PubMed
  134. Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Maor MH, Moots PL, Morrison T, Mrugala MM, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Tran D, Tran N, Vrionis FD, Wen PY, McMillian N, Ho M. Central nervous system cancers. J Natl Compr Canc Netw. 2013 Sep 1; 11(9):1114-51. PMID: 24029126; PMCID: PMC4124889.
  135. Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e396-406. PMID: 23993384.
    View in: PubMed
  136. Chen C, Huang R, MacLean A, Muzikansky A, Mukundan S, Wen PY, Norden AD. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol. 2013 Nov; 115(2):267-76. PMID: 23974656.
    View in: PubMed
  137. Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJ, Wen PY, Ivy P, Batchelor TT, Rosen BR, Jain RK, Sorensen AG. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med. 2013 Sep; 19(9):1178-83. PMID: 23955713; PMCID: PMC3769525.
  138. Cankovic M, Nikiforova MN, Snuderl M, Adesina AM, Lindeman N, Wen PY, Lee EQ. The role of MGMT testing in clinical practice: a report of the association for molecular pathology. J Mol Diagn. 2013 Sep; 15(5):539-55. PMID: 23871769.
    View in: PubMed
  139. Alexander BM, Wen PY, Trippa L, Reardon DA, Yung WK, Parmigiani G, Berry DA. Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro Oncol. 2013 Aug; 15(8):972-8. PMID: 23857706; PMCID: PMC3714161.
  140. Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, Norden AD, Chen H, Wen PY, Drappatz J. Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. J Neurooncol. 2013 Oct; 115(1):71-7. PMID: 23828279.
    View in: PubMed
  141. Huang RY, Rahman R, Hamdan A, Kane C, Chen C, Norden AD, Reardon DA, Mukundun S, Wen PY. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013 Oct 1; 119(19):3479-88. PMID: 23821555.
    View in: PubMed
  142. Wen P, Wang X, Wang J, Zhang B, Qiu G, Fan Y, Xu Y, Tang H, Sun X, Peng Z. A simple technique for a new working heterotopic heart transplantation model in rats. Transplant Proc. 2013 Jul-Aug; 45(6):2522-6. PMID: 23953574.
    View in: PubMed
  143. Lee EQ, Nayak L, Wen PY, Reardon DA. Treatment options in newly diagnosed glioblastoma. Curr Treat Options Neurol. 2013 Jun; 15(3):281-8. PMID: 23553038.
    View in: PubMed
  144. Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, Curry WT, Mitchell DA, Fecci PE, Sampson JH, Dranoff G. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun; 12(6):597-615. PMID: 23750791; PMCID: PMC3982399.
  145. Chinnaiyan P, Won M, Wen PY, Rojiani AM, Wendland M, Dipetrillo TA, Corn BW, Mehta MP. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2013 Aug 1; 86(5):880-4. PMID: 23725999; PMCID: PMC3766839.
  146. Wen P, Nelson KA. Selective enhancements in 2D Fourier transform optical spectroscopy with tailored pulse shapes. J Phys Chem A. 2013 Jul 25; 117(29):6380-7. PMID: 23656554.
    View in: PubMed
  147. Rinne ML, Lee EQ, Nayak L, Norden AD, Beroukhim R, Wen PY, Reardon DA. Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs. 2013 Jun; 18(2):137-53. PMID: 23668489.
    View in: PubMed
  148. Alexander BM, Ligon KL, Wen PY. Enhancing radiation therapy for patients with glioblastoma. Expert Rev Anticancer Ther. 2013 May; 13(5):569-81. PMID: 23617348.
    View in: PubMed
  149. Warren KE, Poussaint TY, Vezina G, Hargrave D, Packer RJ, Goldman S, Wen PY, Pollack IF, Zurakowski D, Kun LE, Prados MD, Rutkowski S, Kieran MW. Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatr Blood Cancer. 2013 Sep; 60(9):1397-401. PMID: 23625747.
    View in: PubMed
  150. Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013 Jul; 15(7):930-5. PMID: 23553268; PMCID: PMC3688016.
  151. Alexander BM, Lee EQ, Reardon DA, Wen PY. Current and future directions for Phase II trials in high-grade glioma. Expert Rev Neurother. 2013 Apr; 13(4):369-87. PMID: 23545053.
    View in: PubMed
  152. Villano JL, Wen PY, Lee EQ, Nayak L, Reardon DA, Rosenfeld MR. PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion. J Neurooncol. 2013 May; 113(1):143-7. PMID: 23479035.
    View in: PubMed
  153. Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, Wen PY, Chen CC, Carter B, Lee JW, Kesari S. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. J Neurosurg. 2013 Jun; 118(6):1183-7. PMID: 23451905.
    View in: PubMed
  154. Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Reply to B. Freidlin et al. J Clin Oncol. 2013 Mar 1; 31(7):970-1. PMID: 23565532.
    View in: PubMed
  155. Wang X, Zielinski MC, Misawa R, Wen P, Wang TY, Wang CZ, Witkowski P, Hara M. Quantitative analysis of pancreatic polypeptide cell distribution in the human pancreas. PLoS One. 2013; 8(1):e55501. PMID: 23383206; PMCID: PMC3561199.
  156. Reardon DA, Groves MD, Wen PY, Nabors L, Mikkelsen T, Rosenfeld S, Raizer J, Barriuso J, McLendon RE, Suttle AB, Ma B, Curtis CM, Dar MM, de Bono J. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res. 2013 Feb 15; 19(4):900-8. PMID: 23363814.
    View in: PubMed
  157. Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM, Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res. 2013 Mar 15; 19(6):1567-76. PMID: 23349317.
    View in: PubMed
  158. Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Target Oncol. 2013 Jun; 8(2):117-25. PMID: 23345034.
    View in: PubMed
  159. Hu J, Wen PY, Abrey LE, Fadul CE, Drappatz J, Salem N, Supko JG, Hochberg F. A phase II trial of oral gimatecan for recurrent glioblastoma. J Neurooncol. 2013 Feb; 111(3):347-53. PMID: 23232808.
    View in: PubMed
  160. Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol. 2012 Dec; 14(12):1511-8. PMID: 23099651; PMCID: PMC3499017.
  161. Zhou SQ, Wen P, Fang L, Jiang L, Xiong M, Zhang FF, Yang JW. The association between RhEPO and FN expression in glomerular mesangial cells. Panminerva Med. 2012 Sep; 54(3):205-9. PMID: 22801437.
    View in: PubMed
  162. Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res. 2012 Nov 01; 18(21):6032-9. PMID: 22923449; PMCID: PMC3947570.
  163. Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, Curry WT, Wen PY, Ligon KL, Ellisen L, Louis DN, Iafrate AJ. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012 Oct; 110(1):89-98. PMID: 22821383; PMCID: PMC3583376.
  164. Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Wen PY, Prados M, Deangelis LM, Omuro A. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 2013 Jan; 54(1):58-61. PMID: 22656234.
    View in: PubMed
  165. Craig JM, Vena N, Ramkissoon S, Idbaih A, Fouse SD, Ozek M, Sav A, Hill DA, Margraf LR, Eberhart CG, Kieran MW, Norden AD, Wen PY, Loda M, Santagata S, Ligon KL, Ligon AH. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One. 2012; 7(6):e38881. PMID: 22719973; PMCID: PMC3376148.
  166. Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol. 2012 Jun; 14(6):761-7. PMID: 22661585; PMCID: PMC3367843.
  167. Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol. 2012 Sep 10; 30(26):3258-63. PMID: 22649140; PMCID: PMC3434985.
  168. Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 Jul; 14(7):819-29. PMID: 22619466; PMCID: PMC3379803.
  169. Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, Gilbert M, Chang S. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012 May; 13(5):e196-204. PMID: 22554547.
    View in: PubMed
  170. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezhnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R, Lorusso P. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol. 2012 Jul 1; 30(19):2307-13. PMID: 22547604.
    View in: PubMed
  171. Rinne ML, Lee EQ, Wen PY. Central nervous system complications of cancer therapy. J Support Oncol. 2012 Jul-Aug; 10(4):133-41. PMID: 22542045.
    View in: PubMed
  172. Lee EQ, Arrillaga-Romany IC, Wen PY. Neurologic complications of cancer drug therapies. Continuum (Minneap Minn). 2012 Apr; 18(2):355-65. PMID: 22810132.
    View in: PubMed
  173. Chamberlain MC, Cloughsey T, Reardon DA, Wen PY. A novel treatment for glioblastoma: integrin inhibition. Expert Rev Neurother. 2012 Apr; 12(4):421-35. PMID: 22449214.
    View in: PubMed
  174. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012 May; 2(5):458-71. PMID: 22588883; PMCID: PMC3354723.
  175. Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Rn PL, Prados M, Goldin J, Wen PY, Cloughesy T. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012 Jul; 108(3):491-8. PMID: 22426926; PMCID: PMC3997502.
  176. Armstrong TS, Wen PY, Gilbert MR, Schiff D. Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol. 2012 Oct; 14(10):1203-14. PMID: 22307472; PMCID: PMC3452334.
  177. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012 Feb; 14(1):48-54. PMID: 22012633.
    View in: PubMed
  178. Das RR, Artsy E, Hurwitz S, Wen PY, Black P, Golby A, Dworetzky B, Lee JW. Outcomes after discontinuation of antiepileptic drugs after surgery in patients with low grade brain tumors and meningiomas. J Neurooncol. 2012 May; 107(3):565-70. PMID: 22212850.
    View in: PubMed
  179. Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, Macdonald DR, Van den Bent MJ, Chang SM. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012 Jan; 70(1):234-43; discussion 243-4. PMID: 21593697.
    View in: PubMed
  180. Chi AS, Wen PY. Inhibiting angiogenesis in malignant gliomas. Handb Clin Neurol. 2012; 104:279-308. PMID: 22230449.
    View in: PubMed
  181. Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012 Apr; 26(4):595-608. PMID: 22193964.
    View in: PubMed
  182. Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM, Jacob A, Kalamarides M, Karajannis MA, Korf BR, Mautner VF, McClatchey AI, Miao H, Plotkin SR, Slattery W, Stemmer-Rachamimov AO, Welling DB, Wen PY, Widemann B, Hunter-Schaedle K, Giovannini M. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A. 2012 Jan; 158A(1):24-41. PMID: 22140088; PMCID: PMC3319201.
  183. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, Jain RK. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 2012 Jan 15; 72(2):402-7. PMID: 22127927; PMCID: PMC3261301.
  184. Alexander BM, Pinnell N, Wen PY, D'Andrea A. Targeting DNA repair and the cell cycle in glioblastoma. J Neurooncol. 2012 May; 107(3):463-77. PMID: 22113697.
    View in: PubMed
  185. Reardon DA, Wen PY, Alfred Yung WK, Berk L, Narasimhan N, Turner CD, Clackson T, Rivera VM, Vogelbaum MA. Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012 Apr; 69(4):849-60. PMID: 22037923.
    View in: PubMed
  186. Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, Gerard M, Schiff D, Chi AS, Batchelor TT, Doherty LM, Ciampa AS, Lafrankie DC, Ruland S, Snodgrass SM, Raizer JJ, Wen PY. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol. 2012 Mar; 107(1):133-8. PMID: 21984064.
    View in: PubMed
  187. Kesselheim JC, Norden AD, Wen PY, Joffe S. Discontinuing bevacizumab in patients with glioblastoma: an ethical analysis. Oncologist. 2011; 16(10):1435-9. PMID: 21948651; PMCID: PMC3228073.
  188. Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012 Jan; 106(2):409-15. PMID: 21938530; PMCID: PMC3616615.
  189. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 2011 Oct; 1(5):442-56. PMID: 22059152.
    View in: PubMed
  190. Wen PY, Schiff D. Valproic acid as the AED of choice for patients with glioblastoma? The jury is out. Neurology. 2011 Sep 20; 77(12):1114-5. PMID: 21880995.
    View in: PubMed
  191. Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011 Oct; 13(10):1118-24. PMID: 21813511; PMCID: PMC3177665.
  192. Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3. PMID: 21768451.
    View in: PubMed
  193. Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S, Prados M. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol. 2012 Jan; 106(1):147-53. PMID: 21739168; PMCID: PMC4351869.
  194. Norden AD, Bartolomeo J, Tanaka S, Drappatz J, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Quant EC, Beroukhim R, Wen PY. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol. 2012 Jan; 106(1):121-5. PMID: 21706358.
    View in: PubMed
  195. Bhatt RS, Zurita AJ, O'Neill A, Norden-Zfoni A, Zhang L, Wu HK, Wen PY, George D, Sukhatme VP, Atkins MB, Heymach JV. Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. Br J Cancer. 2011 Jun 28; 105(1):112-7. PMID: 21673679; PMCID: PMC3137404.
  196. Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011 Jun; 13(6):649-59. PMID: 21636710; PMCID: PMC3107101.
  197. de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res. 2011 Jul 15; 17(14):4872-81. PMID: 21632852; PMCID: PMC3139700.
  198. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011 Jul 01; 29(19):2689-95. PMID: 21606416; PMCID: PMC3139373.
  199. Drappatz J, Raizer JJ, Schiff D, Chi AS, Batchelor T, Snodgrass SM, Quant EC, Norden AD, Beroukhim R, Grimm SA, Doherty LM, Ciampa AS, LaFrankie DC, Ruland S, Gerard M, Hammond S, Wen PY. A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). J Clin Oncol. 2011 May 20; 29(15_suppl):2050. PMID: 28019939.
    View in: PubMed
  200. Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Lamborn K, Wen PY, Prados M, DeAngelis LM, Omuro AM. Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01. J Clin Oncol. 2011 May 20; 29(15_suppl):2039. PMID: 28023834.
    View in: PubMed
  201. Norden AD, Hammond S, Drappatz J, Phuphanich S, Reardon DA, Wong E, Plotkin SR, Lesser GJ, Raizer JJ, Batchelor T, Quant EC, Beroukhim R, Kaley TJ, Muzikansky A, Ciampa AS, Doherty LM, Smith KH, Gerard M, Sceppa C, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2040. PMID: 28023794.
    View in: PubMed
  202. De Groot JF, Cloughesy T, Lieberman FS, Chang SM, Omuro AM, Drappatz J, Batchelor T, DeAngelis LM, Gilbert MR, Yung WK, Fisher JD, Ye X, Lamborn K, Chen AP, Grossman SA, Prados M, Wen PY. Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2043. PMID: 28023799.
    View in: PubMed
  203. Hammond S, Norden AD, Lesser GJ, Drappatz J, Fadul CE, Batchelor T, Quant EC, Beroukhim R, Muzikansky A, Ciampa AS, Doherty LM, LaFrankie DC, Ruland S, Bochacki CA, Griffin K, Gerard M, Sceppa C, Rosenfeld MR, Wen PY. Phase II study of dose-intense temozolomide in recurrent glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):2038. PMID: 28023831.
    View in: PubMed
  204. Quant EC, Batchelor T, Lassman AB, Schiff D, Kaley TJ, Wong E, Mikkelsen T, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, Sceppa C, Gerard M, Hallisey SD, Bochacki CA, Smith KH, Muzikansky A, Wen PY. Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM). J Clin Oncol. 2011 May 20; 29(15_suppl):2069. PMID: 28019932.
    View in: PubMed
  205. Wen PY, Puduvalli VK, Kuhn JG, Reid JM, Lamborn K, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Desideri S, Ye X, Ames MM, Espinoza-Delgado IJ, Grossman SA, Prados M. Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas. J Clin Oncol. 2011 May 20; 29(15_suppl):2032. PMID: 28023819.
    View in: PubMed
  206. Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jun; 13(6):660-8. PMID: 21558074; PMCID: PMC3107095.
  207. Ahluwalia MS, Wen PY. Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions. Expert Rev Anticancer Ther. 2011 May; 11(5):653-6. PMID: 21554035.
    View in: PubMed
  208. van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011 Jun; 12(6):583-93. PMID: 21474379.
    View in: PubMed
  209. Cao Y, Zou SM, Zhang KT, Lu N, Liu Y, Feng L, Wen P, Han NJ, Lin DM. Genetic alterations in pulmonary epithelioid hemangioendothelioma and epithelioid angiosarcoma. Histol Histopathol. 2011 Apr; 26(4):491-6. PMID: 21360442.
    View in: PubMed
  210. Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Vrionis FD, Wen PY. Central nervous system cancers. J Natl Compr Canc Netw. 2011 Apr; 9(4):352-400. PMID: 21464144.
    View in: PubMed
  211. Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR, Chang SM, Lieberman FS, Prados MD, Fine HA. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011 May; 13(5):509-16. PMID: 21377994; PMCID: PMC3093337.
  212. Mellinghoff IK, Lassman AB, Wen PY. Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. Glia. 2011 Aug; 59(8):1205-12. PMID: 21351155.
    View in: PubMed
  213. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61. PMID: 21310734; PMCID: PMC3064608.
  214. Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011 Apr; 13(4):437-46. PMID: 21297127; PMCID: PMC3064694.
  215. Quant EC, Wen PY. Response assessment in neuro-oncology. Curr Oncol Rep. 2011 Feb; 13(1):50-6. PMID: 21086192.
    View in: PubMed
  216. Chaponis D, Barnes JW, Dellagatta JL, Kesari S, Fast E, Sauvageot C, Panagrahy D, Greene ER, Ramakrishna N, Wen PY, Kung AL, Stiles C, Kieran MW. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol. 2011 Aug; 104(1):179-89. PMID: 21246394.
    View in: PubMed
  217. di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011 Jan 1; 71(1):19-28. PMID: 21199795; PMCID: PMC3074948.
  218. Lu-Emerson C, Norden AD, Drappatz J, Quant EC, Beroukhim R, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Wen PY. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J Neurooncol. 2011 Aug; 104(1):287-91. PMID: 21153679.
    View in: PubMed
  219. Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010; 15(12):1329-34. PMID: 21147867; PMCID: PMC3227925.
  220. Young GS, Macklin EA, Setayesh K, Lawson JD, Wen PY, Norden AD, Drappatz J, Kesari S. Longitudinal MRI evidence for decreased survival among periventricular glioblastoma. J Neurooncol. 2011 Aug; 104(1):261-9. PMID: 21132516; PMCID: PMC3151407.
  221. Mou X, Kesari S, Wen PY, Huang X. Crude drugs as anticancer agents. Int J Clin Exp Med. 2011; 4(1):17-25. PMID: 21394282; PMCID: PMC3048980.
  222. Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jan; 13(1):143-51. PMID: 21084434; PMCID: PMC3018914.
  223. Nghiemphu PL, Wen PY, Lamborn KR, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, DeAngelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Demopoulos A, Lassman AB, Kesari S, Mehta MP, Prados MD, Cloughesy TF. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2011 Dec 1; 81(5):1422-7. PMID: 20934264; PMCID: PMC3020272.
  224. Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011 Jun; 103(2):325-32. PMID: 20821342; PMCID: PMC4090923.
  225. Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD. Medical therapies for meningiomas. J Neurooncol. 2010 Sep; 99(3):365-78. PMID: 20820875.
    View in: PubMed
  226. Wen PY. American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section. Expert Rev Anticancer Ther. 2010 Sep; 10(9):1367-9. PMID: 20836670.
    View in: PubMed
  227. Quant EC, Wen PY. Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trials. Neuroimaging Clin N Am. 2010 Aug; 20(3):425-48. PMID: 20708556.
    View in: PubMed
  228. Quant EC, Drappatz J, Wen PY, Norden AD. Recurrent high-grade glioma. Curr Treat Options Neurol. 2010 Jul; 12(4):321-33. PMID: 20842591.
    View in: PubMed
  229. Norden AD, Drappatz J, Wen PY, Claus EB. Survival among patients with primary central nervous system lymphoma, 1973-2004. J Neurooncol. 2011 Feb; 101(3):487-93. PMID: 20556477.
    View in: PubMed
  230. Dou J, Wu Y, Wang J, Zhao F, Chu L, Liu C, Wen P, Hu W, Hu K, He XF, Gu N. Eliciting protective immune responses against murine myeloma challenge in lymphopenia mice through adoptive transfer of tumor antigen-specific lymphocytes and immunization of tumor vaccine secreting mIL-21. Cancer Gene Ther. 2010 Oct; 17(10):675-83. PMID: 20539320.
    View in: PubMed
  231. Passarin MG, Wen PY, Vattemi E, Buffone E, Ghimenton C, Bontempini L, Ottaviani S, Musso AM, Pedersini R. Intravascular lymphomatosis and intracerebral haemorrhage. Neurol Sci. 2010 Dec; 31(6):793-7. PMID: 20517703.
    View in: PubMed
  232. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23. PMID: 20458050; PMCID: PMC2903316.
  233. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010 May-Jun; 60(3):166-93. PMID: 20445000; PMCID: PMC2888474.
  234. Wen PY. Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role? J Clin Oncol. 2010 Apr 20; 28(12):1977-9. PMID: 20308652.
    View in: PubMed
  235. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10; 28(11):1963-72. PMID: 20231676.
    View in: PubMed
  236. Lee JW, Wen PY, Hurwitz S, Black P, Kesari S, Drappatz J, Golby AJ, Wells WM, Warfield SK, Kikinis R, Bromfield EB. Morphological characteristics of brain tumors causing seizures. Arch Neurol. 2010 Mar; 67(3):336-42. PMID: 20212231; PMCID: PMC2995444.
  237. Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol. 2010 Jun; 12(6):603-7. PMID: 20156808; PMCID: PMC2940643.
  238. Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2010 Sep 1; 78(1):85-90. PMID: 20137866.
    View in: PubMed
  239. Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, Sorensen G. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. 2010 May; 12(5):466-72. PMID: 20406897; PMCID: PMC2940624.
  240. Wen PY. Cerebral spinal fluid abnormalities in patients with paraneoplastic syndromes of the nervous system. J Neurol Neurosurg Psychiatry. 2010 Jan; 81(1):3. PMID: 20019217.
    View in: PubMed
  241. Wen PY, Norden AD, Drappatz J, Quant E. Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep. 2010 Jan; 12(1):68-75. PMID: 20425610.
    View in: PubMed
  242. Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal. 2009 Dec 15; 2(101):ra82. PMID: 20009104; PMCID: PMC2978002.
  243. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 2010 Jan; 12(1):87-94. PMID: 20150371; PMCID: PMC2940559.
  244. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 2010 Jan; 12(1):95-103. PMID: 20150372; PMCID: PMC2940554.
  245. Wen PY. New therapies for recurrent glioblastomas. F1000 Med Rep. 2009; 1. PMID: 20948683; PMCID: PMC2948331.
  246. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol. 2009 Dec; 11(6):853-60. PMID: 19293394; PMCID: PMC2802405.
  247. Wen PY, Brandes AA. Treatment of recurrent high-grade gliomas. Curr Opin Neurol. 2009 Dec; 22(6):657-64. PMID: 19770658.
    View in: PubMed
  248. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol. 2009 Nov; 5(11):610-20. PMID: 19826401.
    View in: PubMed
  249. Snuderl M, Eichler AF, Ligon KL, Vu QU, Silver M, Betensky RA, Ligon AH, Wen PY, Louis DN, Iafrate AJ. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res. 2009 Oct 15; 15(20):6430-7. PMID: 19808867; PMCID: PMC2818514.
  250. Wu X, Liu Y, Li X, Wen P, Zhang Y, Long Y, Wang X, Guo Y, Xing F, Gao J. Preparation of aligned porous gelatin scaffolds by unidirectional freeze-drying method. Acta Biomater. 2010 Mar; 6(3):1167-77. PMID: 19733699.
    View in: PubMed
  251. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1; 27(28):4733-40. PMID: 19720927.
    View in: PubMed
  252. Schiff D, Wen PY, van den Bent MJ. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol. 2009 Oct; 6(10):596-603. PMID: 19707193.
    View in: PubMed
  253. Saad AG, Alyea EP, Wen PY, Degirolami U, Kesari S. Graft-versus-host disease of the CNS after allogeneic bone marrow transplantation. J Clin Oncol. 2009 Oct 20; 27(30):e147-9. PMID: 19667266.
    View in: PubMed
  254. Dou J, Li Y, Zhao F, Hu W, Wen P, Tang Q, Chu L, Wang Y, Cao M, Jiang C, Gu N. Identification of tumor stem-like cells in a mouse myeloma cell line. Cell Mol Biol (Noisy-le-grand). 2009; 55 Suppl:OL1151-60. PMID: 19656468.
    View in: PubMed
  255. Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics. 2009 Jul; 6(3):513-26. PMID: 19560741.
    View in: PubMed
  256. Samuel DP, Wen PY, Kieran MW. Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. Expert Opin Investig Drugs. 2009 Jul; 18(7):973-83. PMID: 19548852.
    View in: PubMed
  257. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010 Jan; 96(2):211-7. PMID: 19562255; PMCID: PMC3786190.
  258. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009 Jul 1; 69(13):5296-300. PMID: 19549889; PMCID: PMC2824172.
  259. Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009 Jul 20; 27(21):3518-25. PMID: 19528374; PMCID: PMC2717758.
  260. Lu J, Xue LY, Lu N, Zou SM, Liu XY, Wen P. Superficial primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical analysis of 15 cases. Dis Esophagus. 2010 Feb; 23(2):153-9. PMID: 19515193.
    View in: PubMed
  261. Drappatz J, Norden AD, Wong ET, Lassman AB, Doherty L, LaFrankie D, Gerard M, Phan P, Schiff D, Wen PY. Phase I study of vandetanib with radiation therapy and temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2031. PMID: 27964631.
    View in: PubMed
  262. DePrimo S, Wu B, Huang S, Bautista R, Cancilla B, Vysotskaia V, De Groot J, Prados M, Buller R, Wen P. Correlative tumor molecular profiling and plasma biomarker analysis in a phase II study of XL184 in patients with progressive or recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2009 May 20; 27(15_suppl):2049. PMID: 27964640.
    View in: PubMed
  263. Chi AS, Gerstner ER, Eichler AF, Chea HK, Drappatz J, Wen PY, Ivy SP, Loeffler JS, Sorensen AG, Jain RK, Batchelor TT. Phase Ib study of cediranib in combination with daily temozolomide and radiation in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13010. PMID: 27962847.
    View in: PubMed
  264. Prados M, Gilbert M, Kuhn J, Lamborn K, Cloughesy T, Lieberman F, Puduvalli V, Robins HI, Lassman A, Wen PY. Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J Clin Oncol. 2009 May 20; 27(15_suppl):2005. PMID: 27964562.
    View in: PubMed
  265. De Groot JF, Prados M, Urquhart T, Robertson S, Yaron Y, Sorensen AG, Norton A, Batchelor T, Drappatz J, Wen P. A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse. J Clin Oncol. 2009 May 20; 27(15_suppl):2047. PMID: 27964644.
    View in: PubMed
  266. Kuhn JG, Gilbert M, Wen P, Cloughesy T, Cooper J, Puduvalli V, DeAngelis L, Lieberman F, Lamborn K, Prados M. Interaction between sorafenib and erlotinib. J Clin Oncol. 2009 May 20; 27(15_suppl):2500. PMID: 27961962.
    View in: PubMed
  267. Hu J, Wen PY, Abrey LE, Fadul C, Drappatz J, Salem N, Amato A, Carminati P, Supko J, Hochberg F. Phase II trial of oral gimatecan in adults with recurrent glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2009. PMID: 27964558.
    View in: PubMed
  268. Chang SM, Kuhn J, Lamborn K, Cloughesy T, Robins I, Lieberman F, Yung A, Dancey J, Prados M, Wen P. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02). J Clin Oncol. 2009 May 20; 27(15_suppl):2004. PMID: 27964561.
    View in: PubMed
  269. Batchelor T, Eichler AF, Plotkin SR, Drappatz J, Wen P, Sorensen AG, Gerstner E. Phase I trial of vatalanib (PTK787) in combination with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2035. PMID: 27964624.
    View in: PubMed
  270. Norden AD, Raizer JJ, Lamborn KR, Abrey LE, Chang SM, Gilbert MR, Cloughesy TF, Prados MD, Lieberman F, Wen P. Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas. J Clin Oncol. 2009 May 20; 27(15_suppl):2062. PMID: 27964693.
    View in: PubMed
  271. Sorensen AG, Jenning D, Wang M, Andronesi O, Chen P, Prados M, Wen P, Jackson E, Cha S, deGroot J. Use of neurovascular imaging in GBM patients (pts) to quantify early physiologic changes after treatment with XL184, an inhibitor of multiple receptor tyrosine kinases: Results from a phase II study. J Clin Oncol. 2009 May 20; 27(15_suppl):2048. PMID: 27964638.
    View in: PubMed
  272. Piao Y, Heymach JV, Bekele B, Camphausen K, Wen PY, Liu J, Yung WK, De Groot J. Circulating cytokine and angiogenic factors as predictive biomarkers of glioblastoma response to aflibercept (VEGF Trap). J Clin Oncol. 2009 May 20; 27(15_suppl):2029. PMID: 27964597.
    View in: PubMed
  273. Wen PY, Cloughesy T, Kuhn J, Lamborn K, Abrey LE, Lieberman F, Robins HI, Wright J, Prados MD, Gilbert M. Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). J Clin Oncol. 2009 May 20; 27(15_suppl):2006. PMID: 27964559.
    View in: PubMed
  274. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol. 2009 Jun 20; 27(18):2905-8. PMID: 19451418; PMCID: PMC2702230.
  275. Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009 May; 9(3):231-40. PMID: 19348712.
    View in: PubMed
  276. Drappatz J, Norden AD, Wen PY. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother. 2009 Apr; 9(4):519-34. PMID: 19344303.
    View in: PubMed
  277. Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S, Wen PY. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 2009 Oct; 11(5):550-5. PMID: 19332770; PMCID: PMC2765344.
  278. Gerstner ER, McNamara MB, Norden AD, Lafrankie D, Wen PY. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol. 2009 Aug; 94(1):97-101. PMID: 19221865.
    View in: PubMed
  279. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009 Mar; 144(6):895-903. PMID: 19170677.
    View in: PubMed
  280. Monje M, Wen PY. Neurological complications in adults. Cancer Treat Res. 2009; 150:113-32. PMID: 19834665.
    View in: PubMed
  281. Wen PY. New developments in targeted molecular therapies for glioblastoma. Expert Rev Anticancer Ther. 2009 Jan; 9(1):7-10. PMID: 19105702.
    View in: PubMed
  282. Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009 Jan 1; 15(1):330-7. PMID: 19118062.
    View in: PubMed
  283. Dietrich J, Norden AD, Wen PY. Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr Opin Neurol. 2008 Dec; 21(6):736-44. PMID: 19060566.
    View in: PubMed
  284. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008 Dec; 7(12):1152-60. PMID: 19007739.
    View in: PubMed
  285. Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol. 2009 Apr; 92(2):149-55. PMID: 19043778.
    View in: PubMed
  286. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol. 2008 Nov; 20(6):652-61. PMID: 18841047.
    View in: PubMed
  287. Bracht LK, Wen P, Meyerhardt JA, Kulke MH, Hornick JL, Redston M, LaFrankie DC, Black PM, Kesari S, Norden A, Drappatz J. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. J Clin Oncol. 2008 Oct 10; 26(29):4843-4. PMID: 18779600.
    View in: PubMed
  288. Haining WN, Davies J, Kanzler H, Drury L, Brenn T, Evans J, Angelosanto J, Rivoli S, Russell K, George S, Sims P, Neuberg D, Li X, Kutok J, Morgan J, Wen P, Demetri G, Coffman RL, Nadler LM. CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res. 2008 Sep 1; 14(17):5626-34. PMID: 18765557.
    View in: PubMed
  289. Norden AD, Drappatz J, Ciampa AS, Doherty L, LaFrankie DC, Kesari S, Wen PY. Colon perforation during antiangiogenic therapy for malignant glioma. Neuro Oncol. 2009 Feb; 11(1):92-5. PMID: 18757774; PMCID: PMC2718964.
  290. Fadul CE, Wen PY, Kim L, Olson JJ. Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme. J Neurooncol. 2008 Sep; 89(3):339-57. PMID: 18712284.
    View in: PubMed
  291. Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK. Response criteria for glioma. Nat Clin Pract Oncol. 2008 Nov; 5(11):634-44. PMID: 18711427.
    View in: PubMed
  292. Sauvageot CM, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J, Ramakrishna NR, Stiles CD, Kung AL, Kieran MW, Wen PY. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol. 2009 Apr; 11(2):109-21. PMID: 18682579; PMCID: PMC2718982.
  293. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008 Jul 31; 359(5):492-507. PMID: 18669428.
    View in: PubMed
  294. Kesari S, Drappatz J, Akar S, Vergilio JA, Wen PY, Soiffer RJ, Stone RM, Deangelo DJ. Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass. J Clin Oncol. 2008 Jul 1; 26(19):3279-81. PMID: 18591563.
    View in: PubMed
  295. Gerstner ER, Abrey LE, Schiff D, Ferreri AJ, Lister A, Montoto S, Tsang R, Thiel E, Graus F, Behringer D, Illerhaus G, Weaver S, Wen P, Voloschin A, Harris NL, Batchelor TT. CNS Hodgkin lymphoma. Blood. 2008 Sep 1; 112(5):1658-61. PMID: 18591379; PMCID: PMC3710443.
  296. Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP, DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol. 2008 Aug; 10(4):631-42. PMID: 18559968; PMCID: PMC2666238.
  297. Kesari S, Kim RS, Markos V, Drappatz J, Wen PY, Pruitt AA. Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases. J Neurooncol. 2008 Jun; 88(2):175-83. PMID: 18365144.
    View in: PubMed
  298. Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, Lafrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, Barron L, Sceppa C, Black PM, Wen PY. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009 Jan 1; 73(1):222-7. PMID: 18513880.
    View in: PubMed
  299. Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM, Drappatz J, Ciampa A, Folkman J, Kieran M, Wen PY. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol. 2008 Jun; 10(3):300-8. PMID: 18403492; PMCID: PMC2563052.
  300. Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008 Apr; 8(4):541-53. PMID: 18352856; PMCID: PMC2871667.
  301. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008 Mar 4; 70(10):779-87. PMID: 18316689.
    View in: PubMed
  302. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008 Apr; 10(2):162-70. PMID: 18356283; PMCID: PMC2613818.
  303. Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007 Dec 15; 13(24):7401-6. PMID: 18094423.
    View in: PubMed
  304. Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, Yung WK. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res. 2007 Dec 1; 13(23):7133-8. PMID: 18056194.
    View in: PubMed
  305. Cavaliere R, Wen PY, Schiff D. Novel therapies for malignant gliomas. Neurol Clin. 2007 Nov; 25(4):1141-71, x. PMID: 17964029.
    View in: PubMed
  306. Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther. 2007 Nov; 7(11):1537-60. PMID: 18020923.
    View in: PubMed
  307. Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical management of brain tumor patients. Neurol Clin. 2007 Nov; 25(4):1035-71, ix. PMID: 17964025.
    View in: PubMed
  308. Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol. 2008 Jan; 86(2):211-5. PMID: 17896078.
    View in: PubMed
  309. Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol. 2008 May; 61(6):1059-67. PMID: 17694310; PMCID: PMC3873156.
  310. Wen PY, DeAngelis LM. Chemotherapy for low-grade gliomas: emerging consensus on its benefits. Neurology. 2007 May 22; 68(21):1762-3. PMID: 17515537.
    View in: PubMed
  311. Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol. 2007 Jul; 9(3):354-63. PMID: 17452651; PMCID: PMC1907419.
  312. Ngo TT, Peng T, Liang XJ, Akeju O, Pastorino S, Zhang W, Kotliarov Y, Zenklusen JC, Fine HA, Maric D, Wen PY, De Girolami U, Black PM, Wu WW, Shen RF, Jeffries NO, Kang DW, Park JK. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst. 2007 Apr 18; 99(8):639-52. PMID: 17440165.
    View in: PubMed
  313. Chi AS, Wen PY. Inhibiting kinases in malignant gliomas. Expert Opin Ther Targets. 2007 Apr; 11(4):473-96. PMID: 17373878.
    View in: PubMed
  314. Chheda MG, Drappatz J, Greenberger NJ, Kesari S, Weiss SE, Gigas DC, Doherty LM, Wen PY. Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note. Neurology. 2007 Mar 20; 68(12):955-6. PMID: 17372135.
    View in: PubMed
  315. Monje ML, Ramakrishna NR, Young G, Drappatz J, Doherty LM, Wen PY, Kesari S. Durable response of a radiation-induced, high-grade cerebellar glioma to temozolomide. J Neurooncol. 2007 Sep; 84(2):179-83. PMID: 17332945.
    View in: PubMed
  316. Narin O, Drappatz J, Doherty LM, Wen PY, Kesari S. Cerebrospinal fluid spread of anaplastic glioma. J Clin Oncol. 2007 Feb 10; 25(5):596-7. PMID: 17290068.
    View in: PubMed
  317. Wen PY, Drappatz J. Volumetric MRI- Key to finding better treatments for plexiform neurofibromas? [commentary]. Neurology. 2007; 68:627.
  318. Selected Topics in Cancer Neurology. 2007.
  319. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95. PMID: 17222792; PMCID: PMC2748664.
  320. Drappatz J. Won ET, Schiff D, Gigas D, Doherty L, Kesari S, Batchelor TT, Weiss S, Ramakrishna N, Smith ST. David K, Ostrowsky L, Zimmerman J, Black PM, Wen PY. Pilot safety study of lenalidomdie and radiation therapy in patients with newly diagnosed glioblastoma. American Academy of Neurology 59th Annual Meeting. 2007.
  321. Wen PY, Puduvalli V, Kuhn J, Cloughesy T, Yung WKA, Chang SM, Lamborn K, Robins HI, Ames M, Zweibel J, Prados MD. Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMX) in patients with malignant gliomas (NABTC 04-03). Proc ASCO. 2007.
  322. Abrey LE, Wen PYm, Govindan R, Reimers HJ, Rigas JR, Robins HI, de Bedout S, O'Connell C, Li X, Johri A. Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients with non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II study. Proc ASCO. 2007.
  323. Batchelor TT, Soresen AG, Ancukiewicz M, Duda DG, Louis DN, Plotkin SR, Ivy P, Wen PY, Loeffler J, Jain R. A phase II trial of AZD2171 (cediranib) an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomas. Proc ASCO. 2007; Abstr 2001.
  324. Robins HI, Chang SM, Kuhn J, Lamborn K, Cloughesy T, Gilbert MR, Yung WKA, Dancey J, Prados MD, Wen PY. Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (NABTC 04-02). Proc ASCO. 2007.
  325. Norden AD, Drappatz J, Wen PY. Targeted drug therapy for meningiomas. Neurosurg Focus. 2007; 23(4):E12. PMID: 17961036.
    View in: PubMed
  326. Reardon DA, Groves M, Wen PY, Nabor L, Mikkelsen T, Rosenfel S, Harris D, Demarini D, Suttle B, Arumugham T, Hodge J, Lager J. A Phase II Trial Of Lapatinib And Pazopanib For Patients With Recurrent Glioblastoma Multiforme (GBM). Society For Neuro-Oncology 12th Annual Meeting. 2007.
  327. Schiff D, Wen P. Central nervous system toxicity from cancer therapies. Hematol Oncol Clin North Am. 2006 Dec; 20(6):1377-98. PMID: 17113469.
    View in: PubMed
  328. Maher EA, Brennan C, Wen PY, Durso L, Ligon KL, Richardson A, Khatry D, Feng B, Sinha R, Louis DN, Quackenbush J, Black PM, Chin L, DePinho RA. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 2006 Dec 1; 66(23):11502-13. PMID: 17114236.
    View in: PubMed
  329. Knappenberger KL, Lerch EB, Wen P, Leone SR. Coherent polyatomic dynamics studied by femtosecond time-resolved photoelectron spectroscopy: dissociation of vibrationally excited CS2 in the 6s and 4d Rydberg states. J Chem Phys. 2006 Nov 7; 125(17):174314. PMID: 17100446.
    View in: PubMed
  330. Norden AD, Wen PY. Glioma therapy in adults. Neurologist. 2006 Nov; 12(6):279-92. PMID: 17122724.
    View in: PubMed
  331. Oaklander AL, Richardson PG, Briemberg H, Wen P, Anderson KC, Chan-Khan AA, Schlossmana RL, Munshi NC, Heffner LT< Hassoun H, Avigan DE, Amato A. Multiple myeloma ployneuropath before and after initial chemotherapy with single-agent bortezomib. 131st Annual Meeting of the American Neurological Association. 2006.
  332. Drappatz J, Wen PY. Chemotherapy and targeted molecular therapies for brain metastases. Expert Rev Neurother. 2006 Oct; 6(10):1465-79. PMID: 17078787.
    View in: PubMed
  333. Wen PY, Drappatz J. Novel therapies for meningiomas. Expert Rev Neurother. 2006 Oct; 6(10):1447-64. PMID: 17078786.
    View in: PubMed
  334. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007 Feb; 81(3):271-7. PMID: 17031561.
    View in: PubMed
  335. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jänne PA, Johnson BE. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006 Sep 20; 24(27):4517-20. PMID: 16983123.
    View in: PubMed
  336. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006 Aug 15; 12(16):4899-907. PMID: 16914578.
    View in: PubMed
  337. Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006 Aug 1; 24(22):3651-6. PMID: 16877733.
    View in: PubMed
  338. Doherty L, Gigas DC, Kesari S, Drappatz J, Kim R, Zimmerman J, Ostrowsky L, Wen PY. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology. 2006 Jul 11; 67(1):156-8. PMID: 16832099.
    View in: PubMed
  339. Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L. Medical management of patients with brain tumors. J Neurooncol. 2006 Dec; 80(3):313-32. PMID: 16807780.
    View in: PubMed
  340. Kesari S, Schiff D, Doherty L, Gigas D, Batchelor T, Muzikansky A, O'Neill A, Drappatz J, Kieran M, Wen PY. Phase II study of antiangiogenic (metronomic) chemotherapy for recurrent malignant gliomas. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1569. PMID: 27952494.
    View in: PubMed
  341. Chang SM, Lamborn K, Wen P, Deangelis L, Fink K, Lieberman F, Yung A, Robins I, Cloughesy T, Junck L, Prados M. Phase II study of POLY-ICLC in recurrent anaplastic glioma-A North American Brain Tumor Consortium study. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1550. PMID: 27952599.
    View in: PubMed
  342. Hochberg FH, Supko J, Amato A, Salem N, Carminati P, Wen P. Phase I trial and pharmacokinetic study of oral gimatecan in adults with malignant glioma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1559. PMID: 27952590.
    View in: PubMed
  343. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 Jul 1; 24(19):3113-20. PMID: 16754936.
    View in: PubMed
  344. Wen PY, Kesari S, Drappatz J. Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment. Expert Rev Anticancer Ther. 2006 May; 6(5):733-54. PMID: 16759164.
    View in: PubMed
  345. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006 Apr; 8(2):189-93. PMID: 16533878; PMCID: PMC1871932.
  346. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist. 2006 Feb; 11(2):152-64. PMID: 16476836.
    View in: PubMed
  347. Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Curr Oncol Rep. 2006 Jan; 8(1):58-70. PMID: 16464405.
    View in: PubMed
  348. Ramakrishna N, O'Halloran M, Sullivan S, Kesari S, Wen PY, Bachoo R, Stiles CD. The alkylphospholipd perifosine inhibits Akt and sensitezes murine and human glioma cells to radiation in in vitro and in vivo. Society for Neuro-Oncology 11th Annual Meeting. 2006.
  349. Wen PY. Handbook fo Chemotherapy for Brain Tumors [book review]. Oncology. 2006; 20:430.
  350. Sauvageot C, Barnes J, Weatherbee J, Ramakrishna N, Kung A, Kesari S, Stiles c, Kieran M, Wen PY. Effects of the HSP90 Inhibitor 17-AAG inGlioblastoma Multiforme. Society for Neuro-Oncology 11th Annual Meeting. 2006.
  351. Sauvageot C, Barnes J, Wetherbee J, Ramakrishna N, Kung A, Kesari S, Stiles C, Kieran M, Wen PY. Effects of the HSP90 Inhibitor 17-AAG in Glioblastoma Multiforme. Internation Brain Tumor Research and Therapy Meeting. 2006.
  352. Wen PY, Yung WKA, Lamborn K, Cloughesy T, DeAngelis LM, Fine H, Chang S, Robins HI, Fink K, Abrey L, Lassman A, Mehta M, Kim L, Stiles C, Egorin M, Capdeville R, Kaplan R, Murgo A, Prados MD. Phase II Study of Imatinib Mesylate (STI571) for Patients with Recurrent Meningiomas (NABTC 01-08). Socity for Neuro-Oncology 11th Annual Meeting. 2006.
  353. Barnes JW, Cervi D, Ligon KL, Tseng KL, Longtine J A, Chaponis DM, Wen PY, Kesaris, Drappatz J, Black PM, Kieran MW. High throughput proteomic identification and quantification of MGMT in human brain tumors. Society for Neuro-Oncology 11th Annual Meeting. 2006.
  354. Wen PY, Kesari S, Grier J. Neurologic complications of chemotherapy. Medlink. 2006.
  355. Medical Management of Brain Tumors. 2006.
  356. Hochberg FH, Supko JG< Amato A, Salem N, Zhang D, Carminati P, Wen PY, Szylleyko O. A Phase I Clinical Trial and Phamacokinetic Study of Oral ST1481 in Adults with Malignant Glioma. Proc ASCO. 2006.
  357. Targeted Molecular Therapies for Brain Tumors. 2006.
  358. Wen PY, Chang SM< Kuhn J, Lamborn K, Robins HI, Cloughesy T, Gilbert MR, Yung WKA, Mehta M, DEAngelis LM, Abrey LE, Kesari S, Drappatz J, Lassman A, Dancey J, Prados MD. Phase I study of erlotinib and temsirolimus in patients with recurrent malignant gliomas (NABTC 04-02). Society for Neuro-Oncology 11th Annual Meeting. 2006.
  359. Shah GD, Kesari S, Xu R, Batchelor TT, O'Neill AM, Hochberg FH, Levy B, Bradshaw J, Wen PY. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro Oncol. 2006 Jan; 8(1):38-46. PMID: 16443946; PMCID: PMC1871928.
  360. Barnes J, Sauvageot C, Kung A, Ramakrishna N, Stiles C, Chaponis D, Wen PY, Kieran M. SCH66336 (Sarasar(R)), an Oral Farnesyl Transferase Inhibitor, Synergizes with Temozolomide and Radiation Therapy for Orthotopic Malignant Gliomas. International Brain Tumor Research and Therapy Meeting. 2006.
  361. Norden AD, Wen PY, Kesari S. Brain metastases. Curr Opin Neurol. 2005 Dec; 18(6):654-61. PMID: 16280676.
    View in: PubMed
  362. Lassman AB, Rossi MR, Raizer JJ, Razier JR, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M, Holland EC. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res. 2005 Nov 1; 11(21):7841-50. PMID: 16278407.
    View in: PubMed
  363. Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebti SM, Prados M. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2005 Sep 20; 23(27):6647-56. PMID: 16170172.
    View in: PubMed
  364. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005 Aug; 23(4):357-61. PMID: 16012795.
    View in: PubMed
  365. Lu C, Gonzalez RG, Jolesz FA, Wen PY, Talcott JA. Suspected spinal cord compression in cancer patients: a multidisciplinary risk assessment. J Support Oncol. 2005 Jul-Aug; 3(4):305-12. PMID: 16092602.
    View in: PubMed
  366. Kesari S, Ramakrishna N, Sauvageot C, Stiles CD, Wen PY. Targeted molecular therapy of malignant gliomas. Curr Neurol Neurosci Rep. 2005 May; 5(3):186-97. PMID: 15865884.
    View in: PubMed
  367. Wen PY. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clin Cancer Res. 2005 Mar 1; 11(5):1685-6. PMID: 15755987.
    View in: PubMed
  368. Kesari S, Wen PY. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial [commentary]. Neurology. 2005; 64.
  369. Drappatz J, Wen PY. Management of seizures in patients with primary and metastatic brain tumors. UpToDate. 2005.
  370. bolar TS, Benner T, Hodge RD, Pectasides M, Wiggins CJ, George DJ, Wen PY, Sorenson AG. Perfusion Imaging of Hemangioblastoma: Implications for using arterial spin labeling to characterize tumor dynamics. ISMR. 2005.
  371. Wen PY, Schiff D, doherty L, Gigas DC, Musikansky A, Bradshaw J, Levy B, Kesari S, Ramakrishna N, Maher EA, Black PM. A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma. Proc ASCO. 2005.
  372. Drappatz J, Wen PY. Chemotherapy for brain metastases. Up-To-Date. 2005.
  373. Wen PY. Cnetral Nervous system Tumors. American Society of Clincial Oncology 2005 Annual Meeting Summaries. 2005; 32-40.
  374. Wen PY, MacDonald L, Gigas DC. Management of non-neoplastic problems in brain tumor patients. Black PM, Loeffler JS, editors. Cancer of Nervous System. 2005; 243-254.
  375. Hart RG, Wen PY. Anticoagulant and antiplatelet therapy in patients with brain tumors. UpToDate. 2005.
  376. Reardon DA, Wen P, Lyons P, Knowles HL, Bedrosian CL, Friedman H. A Phase I trial of AP23573, a novel mTOR Inhibitor in patients with recurrent malignant glioma. AARC-NCI-EORTC Internation Conference on Melecular Targets and Cancer Therapeutics. 2005.
  377. Lassman AB, Ross MR, Razier JR, Abrey LA, Grefe CN, Lamborn K, Pao W, Shih AH, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, Wen P, Gilbert MR, Chang S, Yung WKA, Prados M, Holland EC. Molecular study of malignant gliomas treated with the EGFR inhibitor, elotinib (OSI-774): Tissue analysis from a North American Brain Tumor Consortium (NABTC) study. Clin Cancer Res. 2005; 11:7841-7850.
  378. Wen PY, Teoh SK, gigas DC, Macdonald LM. Presentations and Approaches to Patients with Brain Tumors. Schiff D, O'Neil BP, editors. cancer in the Nervous System. 2005.
  379. Wen PY, Loeffler JS. Treatment of brain metastases in good prognosis patients. Up-To-Date. 2005.
  380. Drappatz J, Wen PY. Palliative Care Consultations- Primary and metastatic brain tumours, Oxford Press, 2005, Booth and Bruera (eds) [book review]. J Palliative Care. 2005; (8):1068-9.
  381. Targeted Molecular Therapies for Malignant Gliomas. 2005.
  382. Drappatz J, Wen PY. Palliative Care in Neurology, Oxford Press 2004. Voltz et al. (eds) [book review]. j Palliative Care. 2005; 8:1067-8.
  383. Yung WKA, Lieberman FS, Wen P, et al. Combination of Temozolomide and Irinotecan showed enhanced activity for recurrent malignant gliomas: A North American Brain Tumor Consoritum (NABTC) Phase II study. Proc ASCO. 2005.
  384. Drappatz J, Wen PY. Management of vasogenic edema in patients with brain tumors. Up-To-Date. 2005.
  385. Update of Radiosurgery for Brain Metastases. Update of Radiosurgery for Brain Metastases. 2005.
  386. Wen PY, Loeffler JS. Overview of brain metastases. Up-to-Date. 2005.
  387. Cloughesy TF, Kuhn J, Robins HI, Abrey A, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Wright J, Lamborn K, Sebti S, Prados, M. A Phase I Trial of R115777 in Patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs (EIAEDs): A North American Brian Tumor Consortium Study. J Clin Oncol. 2005; (23):6647-6656.
  388. Richardson P, Chanan-Khan A, Schlossman R, Munshi N, Wen PY, Kesari S, Briemberg H, Kuter D, Oaklander A, Lonial S, Hassoun H, Doss D, Lunde L, Dinand K, McAlister C, Warren D, Collins D, Esseltine D, Amato A, Anderson KC. A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly Hgi9h Rates of Baseline Peripheral Neuropathy. American Society for Hematology 47th Annual Meeting. 2005.
  389. Wen PY, Loeffler JS. Treatment of Brain Metastases in poor prognosis patients. Up-To-Date. 2005.
  390. Drappatz J, Wen PY. Non-cytotoxic drugs as potential treatments for gliomas. Curr Opin Neurol. 2004 Dec; 17(6):663-73. PMID: 15542974.
    View in: PubMed
  391. Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs. 2004 Nov; 22(4):427-35. PMID: 15292713.
    View in: PubMed
  392. Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 2004 Nov 01; 22(21):4282-9. PMID: 15514370; PMCID: PMC3820102.
  393. Mrugala MM, Kesari S, Ramakrishna N, Wen PY. Therapy for recurrent malignant glioma in adults. Expert Rev Anticancer Ther. 2004 Oct; 4(5):759-82. PMID: 15485312.
    View in: PubMed
  394. Shah G, Kesari S, Xu R, Henson J, Batchelor T, Hochberg F, Oneill A, Levy B, Bradshaw J, Wen PY. Comparison of 1D, 2D, 3D and volumetric parameters in measuring tumor response in high-grade gliomas in adults. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1523. PMID: 28015429.
    View in: PubMed
  395. Raizer JJ, Abrey LE, Wen P, Cloughesy T, Robins IA, Fine HA, Lieberman F, Puduvalli VK, Fink KL, Prados M. A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1502. PMID: 28015384.
    View in: PubMed
  396. Lieberman FS, Cloughesy T, Fine H, Kuhn J, Lamborn K, Malkin M, Robbins HI, Yung WA, Wen P, Prados M. NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1510. PMID: 28015363.
    View in: PubMed
  397. Supko JG, Alderson L, Wen P, Cassidy K, Pace S, Obrocea M, Hochberg F. Pharmacokinetics of gimatecan, and orally administered camptothecin analogue, in patients with malignant gliomas. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2039. PMID: 28015627.
    View in: PubMed
  398. Prados M, Yung W, Wen P, Junck L, Fink K, Cloughesy T, Robins I, Chang S, Kuhn J. Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1504. PMID: 28015386.
    View in: PubMed
  399. Wen PY, Kesari S. Malignant gliomas. Curr Neurol Neurosci Rep. 2004 May; 4(3):218-27. PMID: 15102348.
    View in: PubMed
  400. Lieberman F, Cloughesy T, Fine H, Kuhn J, Lamborn K, Malkin M, Robbins HI, Yung WA, Wen P, Prados M. NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. Proc ASCO. 2004.
  401. Raizer JJ, Abrey L, Wen P, Cloughesy T, Robins IA, Fine HA, Lieberman F, Puduvalli VK, Fink KL, Prados M. A Phase II trial of OSI-774 (Tarceva) in patients with Recurrent Malignant Gliomas not on EIAEDs. Proc ASCO. 2004.
  402. Voloshcin AD, Wen PY, Lawler B, Ciordia R, Hochberg FH, Batchelor TT. Topotecan as salvage therapy for refractory or relapsed primary central nervous system lymphoma: Final Report. American Academy of Neuorlogy, 56th Annual Meeting. 2004.
  403. Cavaliere R, Farace E, Wen P, Schiff D. Thalidomide-induced thromboembolic events in patients with high-grade gliomas. Neuro-Oncology. 2004; Abstr TA-11.
  404. Brain Metastases-Emerging role of Radiosurgery. 2004.
  405. Neurologic Complications of Cancer Therapy. 2004.
  406. Supko JG, Alderson L, Wen P, Cassidy K, Pace S, Obrocea M, Hochberg F. Pharmacokinetics of gimatecan and orally administerd camptothecin analogue, in patients with malignant gliomas. Proc ASCO. 2004.
  407. Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan; 6(1):44-54. PMID: 14769140; PMCID: PMC1871968.
  408. Wen PY, Ramakrishna N, Fisher DC. Neurologic complications of lymphoma therapy. Batchelor TT, editor. Nervous System Lymphoma. 2004; 149-182.
  409. Kesari S, Wen PY. Neuro-Oncology. Samuels MA, editor. Manual of Neurologic Therapeutics. 2004; 115-178.
  410. Schiff D, Wen PY. Nervous system metastases. Bradley W, Daroff R, Fenichel G, Jankovic J, editors. Neurology in Clinical Practice. 2004; 1441-1460.
  411. Richardson PG, Chana-Khan A, Schlossman R, Munshi M, Wen PY, Briemberg H, Kuter K, Oaklander A-L, Lonial S, Hassoun H, Doss D, Lunde L, Dinand K, McAlister C, Warren D, Collins D, Esseltine D, Amato A, Anderson KC. Phase II Trial of Single Agent VELCADE (bortezomib) in patients with previously untreated multiple myeloma. American Society for Hematology 46th Annual Meeting. 2004.
  412. Wen PY, Kesari S, Hsu L, De Girolami U. Brain Tumors. Baker and Joynt's Clinical Neurology on CD-ROM. 2004.
  413. Ramakrishna N, Galper S, Wen PY. Brain Metastases in patients with breast cancer. Harris J, Lippman M, Morrow M, Kent Osborne C, editors. Diseases of the Breast. 2004; 1205-1218.
  414. Wen PY, McColl CD, Freilich RJ. Epidural disease. Harris J, Lippman M, Morrow M, Kent Osborne C, editors. Diseases of the Breast. 2004; 1219-1231.
  415. Wen PY, gigas DC, MacDonald L, Batchelor TT, Schiff D, Xu R, Ramakrishna N, Weaver S, Kracher J, Bradshaw J, Levy B, Bailey E, Kesari S, Maher EA, Henson J, Black PM. Phase II Study of Temozolomide, Thalidomide and Celecoxib in Patients with Newly-Diagnosed Glioblastomas Multiforme in the Post-Radiation Setting. Neuro-Oncology. 2004; Abstr. TA-64.
  416. Prados M, Yung W, Wen P, Junck L, Fink K, Cloughesy T, Robins IA , Chang S, Kuhn J. Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A North American Brain Tumor Consortium study. Proc ASCO. 2004.
  417. Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol. 2003 Jun 15; 21(12):2299-304. PMID: 12805330.
    View in: PubMed
  418. Wen PY, Schiff D. Neurologic complications of solid tumors. Neurol Clin. 2003 Feb; 21(1):107-40, viii. PMID: 12690647.
    View in: PubMed
  419. Wen PY, Glantz MJ. Neurologic complications of cancer. Preface. Neurol Clin. 2003 Feb; 21(1):xi-xiii. PMID: 12690642.
    View in: PubMed
  420. Plotkin SR, Wen PY. Neurologic complications of cancer therapy. Neurol Clin. 2003 Feb; 21(1):279-318, x. PMID: 12690653.
    View in: PubMed
  421. Wen PY. Neurologic complications of bone marrow transplantation. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1166-1171.
  422. Wen PY, Kesari S. Neurologic complications of chemotherapy. Medlink Neurology. 2003.
  423. Wen PY, Fine HA, Loeffler JS, Black P. Malignant Gliomas. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1038-1048.
  424. Schiff D, Wen PY, Hsu L. Uncommon brain tumors, skull base tumors, and intracranial cysts. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1092-1100.
  425. Plotkin S, Wen PY. Brain Metastases. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1134-1140.
  426. Wen PY, Teoh SK. Clinical Presentation and Diagnosis of Brain Tumors. Samuels MA, Fesk S, editors. Office Practice of Neurology. 2003; 1013-1017.
  427. Wen PY, Ramakrishna, N. General principles of management of patients with brain tumors. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1018-1024.
  428. Schiff D, Trump D, Wen P. Neurologic Complications of Genitourinary Malignancies. Schiff D, Wen PY, editors. Cancer Neurology in Clinical Practice. 2003; 327-338.
  429. Schiff D, Wen PY, editors. Cancer Neurology in Clinical Practice. 2003.
  430. Lieberman, Cloughesy T, Deangelis L, Fine H, Fink K, Junck L, Kuhn J, Mehta M, Wen P, Prados M. Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy. ASCO. 2003.
  431. Wen PY. CNS complications of Cancer Therapy. Schiff D, Wen P, editors. Cancer Neurology in Clinical Practice. 2003; 215-231.
  432. Brain Metastases-Emerging Role of Radiosurgery. 2003.
  433. Wen PY, Schiff D, MacDonald L, Gigas DC, Ramakrishna N, Batchelor TT, Xu R, Slate A, Levy B, Bradshaw J, Black PM, Folkman J, Kieran M. Phase II Study of Antiangiogenic Chemotherapy for Recurrenct Malignant Glioma. Neuro-Oncology. 2003; 5:357. Abstr TA-41.
  434. Wen PY. Encephalopathy and Neuropathy. Furie B, Atkins M, Cassieth P, Mayer R, editors. Clinical Practice of Hematology-Oncology: Presentations, Diagnosis and Treatment. 2003; 32-41.
  435. Alderson L, Supko J, Hochberg F, Wen P, Maestri X, Sampath P, Benincasa E, Belonogova N, Zanna C, Carminati P, Chabner B, Calabresi P. Phase I/II trial of gimatecan in patients with recurrent maligngant glioma. Neuro Oncology. 2003; 5:347. Abstr TA-01.
  436. Gilber MR, Wen P, Lieberman F, Robins I, Mehta M, Yung WKA, Chang S, Junck L, Cloughesy T, Prados M. Phase I/II study of combination temozolomide (TMZ) and irinotecan (CPT-11) for recurrent malignant gliomas: A North American Brain Tumor Consurotium (NABTC) study. ASCO. 2003.
  437. Plotkin S, Wen PY. Brain Metastases. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1101-1107.
  438. Wen PY, Glantz MJ, editors. Neurologic Complications of Cancer. Neurol Clinics. 2003.
  439. Wen PY. Neurologic complications of chemotherapy. Samuels MA, Feske S, editors. Office Practice of Neurology. 2003; 1134-1140.
  440. Jeter MD, Jänne PA, Brooks S, Burstein HJ, Wen P, Fuchs CS, Loeffler JS, Devlin PM, Salgia R. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002 Jun 1; 53(2):394-400. PMID: 12023144.
    View in: PubMed
  441. Wen PY, Marks PW. Medical management of patients with brain tumors. Curr Opin Oncol. 2002 May; 14(3):299-307. PMID: 11981275.
    View in: PubMed
  442. Plotkin S, PY Wen. Neurologic complications of cancer therapy. Up-To-Date in Oncology. 2002.
  443. PY Wen. Brain Metastases. Up-To-Date in Oncology. 2002.
  444. PY Wen, Bachoo R. Management of Brain Tumors. Up-To-Date in Oncology. 2002.
  445. Blankenberg FG, Wen P, Dai M, Zhu D, Panchal SN, Tait JF, Post AM, Strauss HW, Valantine HA. Detection of early atherosclerosis with radiolabeled monocyte chemoattractant protein-1 in prediabeteic Zucker rats. Pediatr Radiol. 2001 Dec; 31(12):827-35. PMID: 11727015.
    View in: PubMed
  446. Schiff D, O'Neill B, Wijdicks E, Antin JH, Wen PY. Gliomas arising in organ transplant recipients: an unrecognized complication of transplantation? Neurology. 2001 Oct 23; 57(8):1486-8. PMID: 11673595.
    View in: PubMed
  447. Baki L, Marambaud P, Efthimiopoulos S, Georgakopoulos A, Wen P, Cui W, Shioi J, Koo E, Ozawa M, Friedrich VL, Robakis NK. Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 association, and regulates stability and function of the cadherin/catenin adhesion complex. Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5):2381-6. PMID: 11226248; PMCID: PMC30147.
  448. Wen PY, Teoh SK, Black PM. Clinical Imaging and Diagnosis of Brain Tumors. Laws E, Kaye A, editors. Brain Tumors. 2001; 217-248.
  449. Wen PY, Black PM, Loeffler JS. Metastatic Brain Cancer. DeVita VT, Hellman S, Rosenberg SA, editors. Principles and Practice of Oncology. 2001; 2655-2670.
  450. Park CC, Hartmann C, Folkerth R, Loeffler JS, Wen PY, Fine HA, Black PM, Shafman T, Louis DN. Systemic metastasis in glioblastoma may represent the emergence of neoplastic subclones. J Neuropathol Exp Neurol. 2000 Dec; 59(12):1044-50. PMID: 11138924.
    View in: PubMed
  451. Wen PY, Loeffler JS. Brain metastases. Curr Treat Options Oncol. 2000 Dec; 1(5):447-58. PMID: 12057152.
    View in: PubMed
  452. Vorachek WR, Steppan CM, Lima M, Black H, Bhattacharya R, Wen P, Kajiyama Y, Locker J. Distant enhancers stimulate the albumin promoter through complex proximal binding sites. J Biol Chem. 2000 Sep 15; 275(37):29031-41. PMID: 10842175.
    View in: PubMed
  453. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, Grossman SA, Cairncross JG. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 May 23; 54(10):1886-93. PMID: 10822423.
    View in: PubMed
  454. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000 Feb; 18(4):708-15. PMID: 10673511.
    View in: PubMed
  455. wen PY, Shafman T. Brain metastases in patients with breast cancer. Harris J, Lippman M, Morrow M, Kent Osborne C, editors. Disease of the Breast. 2000.
  456. Glanz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, Grossman SA, Cairncross JG. Practice parameters: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology. 2000; 54:1886-1893.
  457. Wen PY, Loeffler JS. Management of brain metastases. Oncology (Williston Park). 1999 Jul; 13(7):941-54, 957-61; discussion 961-2, 9. PMID: 10442342.
    View in: PubMed
  458. Mamon HJ, Wen PY, Burns AC, Loeffler JS. Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia. 1999 Mar; 40(3):341-4. PMID: 10080516.
    View in: PubMed
  459. Wen PY. Spinal Ependymomas. Gilman S, Goldstein GW, Waxman SG, editors. Neurobase. 1999.
  460. Shrieve DC, Alexander E, Black PM, Wen PY, Fine HA, Kooy HM, Loeffler JS. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg. 1999 Jan; 90(1):72-7. PMID: 10413158.
    View in: PubMed
  461. Mao H, Zhang L, Wang Y, Wen P, Cui S. [Influence of icariin on cell membrane of highly metastatic human lung tumor cell line]. Zhong Yao Cai. 1999 Jan; 22(1):35-6. PMID: 12575062.
    View in: PubMed
  462. Role of chemotherpay in patients with gliomas. 1999.
  463. Talcott JA, Stomper PC, Drislane FW, Wen PY, Block CC, Humphrey CC, Lu C, Jolesz F. Assessing suspected spinal cord compression: a multidisciplinary outcomes analysis of 342 episodes. Support Care Cancer. 1999 Jan; 7(1):31-8. PMID: 9926972.
    View in: PubMed
  464. Wen PY, Black PB. Clinical Presentation, Evaluation and Preoperative Preparation of the Patient. Berger MS, Wilson CB, editors. Textbook of Gliomas. 1999; 328-344.
  465. Lu C, Stomper PC, Drislane FW, Wen PY, Block CC, Humphrey CC, Collins CA, Jolesz F, Talcott JA. Suspected spinal cord compression in breast cancer patients: a multidisciplinary risk assessment. Breast Cancer Res Treat. 1998 Sep; 51(2):121-31. PMID: 9879774.
    View in: PubMed
  466. Lea-Currie YR, Wen P, McIntosh MK. Dehydroepiandrosterone reduces proliferation and differentiation of 3T3-L1 preadipocytes. Biochem Biophys Res Commun. 1998 Jul 30; 248(3):497-504. PMID: 9703954.
    View in: PubMed
  467. Manome Y, Kunieda T, Wen PY, Koga T, Kufe DW, Ohno T. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther. 1998 Jul 1; 9(10):1409-17. PMID: 9681412.
    View in: PubMed
  468. Kassis AI, Wen PY, Van den Abbeele AD, Baranowska-Kortylewicz J, Makrigiorgos GM, Metz KR, Matalka KZ, Cook CU, Sahu SK, Black PM, Adelstein SJ. 5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med. 1998 Jul; 39(7):1148-54. PMID: 9669385.
    View in: PubMed
  469. Schiff D, Batchelor T, Wen PY. Neurologic emergencies in cancer patients. Neurol Clin. 1998 May; 16(2):449-83. PMID: 9537970.
    View in: PubMed
  470. Parr MJ, Wen PY, Schaub M, Khoury SJ, Sayegh MH, Fine HA. Immune parameters affecting adenoviral vector gene therapy in the brain. J Neurovirol. 1998 Apr; 4(2):194-203. PMID: 9584956.
    View in: PubMed
  471. Hakim R, Alexander E, Loeffler JS, Shrieve DC, Wen P, Fallon MP, Stieg PE, Black PM. Results of linear accelerator-based radiosurgery for intracranial meningiomas. Neurosurgery. 1998 Mar; 42(3):446-53; discussion 453-4. PMID: 9526976.
    View in: PubMed
  472. Apergis GA, Crawford N, Ghosh D, Steppan CM, Vorachek WR, Wen P, Locker J. A novel nk-2-related transcription factor associated with human fetal liver and hepatocellular carcinoma. J Biol Chem. 1998 Jan 30; 273(5):2917-25. PMID: 9446603.
    View in: PubMed
  473. Chang EL, Loeffler JS, Riese NE, Wen PY, Alexander E, Black PM, Coleman CN. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. Int J Radiat Oncol Biol Phys. 1998 Jan 1; 40(1):65-70. PMID: 9422559.
    View in: PubMed
  474. Feske S, Wen PY, editors. Emergency Neurology. Neurologic clinics. 1998.
  475. Wen PY, Alyea EP, Simon D, Herbst RS, Soiffer RJ, Antin JH. Guillain-Barré syndrome following allogeneic bone marrow transplantation. Neurology. 1997 Dec; 49(6):1711-4. PMID: 9409375.
    View in: PubMed
  476. Tomashefski JF, Wen P, Giampoli E, Doershuk CF, Stern RC, Dahms B. Pulmonary intralobar sequestration in a patient with cystic fibrosis. Hum Pathol. 1997 Dec; 28(12):1436-9. PMID: 9416704.
    View in: PubMed
  477. Lea-Currie YR, Wen P, McIntosh MK. Dehydroepiandrosterone-sulfate (DHEAS) reduces adipocyte hyperplasia associated with feeding rats a high-fat diet. Int J Obes Relat Metab Disord. 1997 Nov; 21(11):1058-64. PMID: 9368831.
    View in: PubMed
  478. Parr MJ, Manome Y, Tanaka T, Wen P, Kufe DW, Kaelin WG, Fine HA. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med. 1997 Oct; 3(10):1145-9. PMID: 9334729.
    View in: PubMed
  479. Wen PY, Feske SK, Teoh SK, Stieg PE. Cerebral hemorrhage in a patient taking fenfluramine and phentermine for obesity. Neurology. 1997 Aug; 49(2):632-3. PMID: 9270617.
    View in: PubMed
  480. Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med. 1997 Apr; 3(4):437-42. PMID: 9095178.
    View in: PubMed
  481. Fine HA, Wen PY, Robertson M, O'Neill A, Kowal J, Loeffler JS, Black PM. A phase I trial of a new recombinant human beta-interferon (BG9015) for the treatment of patients with recurrent gliomas. Clin Cancer Res. 1997 Mar; 3(3):381-7. PMID: 9815695.
    View in: PubMed
  482. Sahu SK, Wen PY, Foulon CF, Nagel JS, Black PM, Adelstein SJ, Kassis AI. Intrathecal 5-[125I]iodo-2'-deoxyuridine in a rat model of leptomeningeal metastases. J Nucl Med. 1997 Mar; 38(3):386-90. PMID: 9074525.
    View in: PubMed
  483. Lynch TJ, Lambert JM, Coral F, Shefner J, Wen P, Blattler WA, Collinson AR, Ariniello PD, Braman G, Cook S, Esseltine D, Elias A, Skarin A, Ritz J. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol. 1997 Feb; 15(2):723-34. PMID: 9053498.
    View in: PubMed
  484. Wen PY, Fine HA. Leptomeningeal Metastases. Black PMcL, Loeffler JS, editors. Cancer of the Nervous System. 1997; 288-309.
  485. Wen PY. Diagnosis of Management of Brain Tumors. Black PMcL, Loeffler JS, editors. Cancer of the Nervous System. 1997; 106-127.
  486. Packard AB, Barbarics E, Kronauge JF, Wen PY, Day PJ, Jones AG. Comparison of uptake of 99mTc-alkylisonitriles in the rat 9L gliosarcoma tumor model. Nucl Med Biol. 1997 Jan; 24(1):21-5. PMID: 9080471.
    View in: PubMed
  487. Tanaka T, Manome Y, Wen PY, Kufe D, Fine HA. Retroviral-meicated transduction of a modified platelet factor-4 cDNA inhibits angiogenesis and tumor growth. Nature Medicine. 1997; 3:437-442.
  488. Wen PY. Neurologic Complications of Chemotherapy. Gilman S, Goldstein GW, Waxman SG, editors. Neurobase. 1997.
  489. Manome Y, Wen PY, Chen L, Tanaka T, Dong Y, Yamazoe M, Hirshowitz A, Kufe DW, Fine HA. Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther. 1996 Jun; 3(6):513-20. PMID: 8789801.
    View in: PubMed
  490. Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell BS, Kufe DW, Fine HA. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med. 1996 May; 2(5):567-73. PMID: 8616717.
    View in: PubMed
  491. Dong Y, Wen P, Manome Y, Parr M, Hirshowitz A, Chen L, Hirschowitz EA, Crystal R, Weichselbaum R, Kufe DW, Fine HA. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther. 1996 Apr 10; 7(6):713-20. PMID: 8919593.
    View in: PubMed
  492. Kassis AI, Tumeh SS, Wen PY, Baranowska-Kortylewicz J, Van den Abbeele AD, Zimmerman RE, Carvalho PA, Garada BM, DeSisto WC, Bailey NO, Castronovo FP, Mariani G, Black PM, Adelstein SJ. Intratumoral administration of 5-[123I]iodo-2'-deoxyuridine in a patient with a brain tumor. J Nucl Med. 1996 Apr; 37(4 Suppl):19S-22S. PMID: 8676198.
    View in: PubMed
  493. Neurologic complications of cancer. 1996.
  494. Management of Patients with brain tumors. 1996.
  495. Gaa J, Warach S, Wen P, Thangaraj V, Wielopolski P, Edelman RR. Noninvasive perfusion imaging of human brain tumors with EPISTAR. Eur Radiol. 1996; 6(4):518-22. PMID: 8798035.
    View in: PubMed
  496. Schiff D, Wen PY. Uncommon brain tumors. Neurol Clin. 1995 Nov; 13(4):953-74. PMID: 8584006.
    View in: PubMed
  497. Wen PY, Fine HA, Black PM, Shrieve DC, Alexander E, Loeffler JS. High-grade astrocytomas. Neurol Clin. 1995 Nov; 13(4):875-900. PMID: 8584002.
    View in: PubMed
  498. Manome Y, Wen PY, Hershowitz A, Tanaka T, Rollins BJ, Kufe DW, Fine HA. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol Immunother. 1995 Oct; 41(4):227-35. PMID: 7489565.
    View in: PubMed
  499. Geller EB, Wen PY. Migraine with aura as the presentation of leukemia. Headache. 1995 Oct; 35(9):560-2. PMID: 8530284.
    View in: PubMed
  500. Loeffler JS, Shrieve DC, Wen PY, Fine HA, Kooy HM, Addesa AE, Black PM, Alexander E. Radiosurgery for Intracranial Malignancies. Semin Radiat Oncol. 1995 Jul; 5(3):225-234. PMID: 10717146.
    View in: PubMed
  501. Jin JR, Wen P, Locker J. Enhancer sharing in a plasmid model containing the alpha-fetoprotein and albumin promoters. DNA Cell Biol. 1995 Mar; 14(3):267-72. PMID: 7533503.
    View in: PubMed
  502. Shrieve DC, Alexander E, Wen PY, Fine HA, Kooy HM, Black PM, Loeffler JS. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 1995 Feb; 36(2):275-82; discussion 282-4. PMID: 7731507.
    View in: PubMed
  503. Alexander E, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, Kooy HM, Loeffler JS. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst. 1995 Jan 4; 87(1):34-40. PMID: 7666461.
    View in: PubMed
  504. Wen PY, Loeffler JS. Advances in the diagnosis and management of pituitary tumors. Curr Opin Oncol. 1995 Jan; 7(1):56-62. PMID: 7696364.
    View in: PubMed
  505. Uncommon Brain Tumors. 1995.
  506. Neurologic complications of brain tumor therapy. 1995.
  507. Black PM, Wen P. Clinical Imaging and Laboratory Diagnosis of Brain Tumors. Kaye A, Shaw E, editors. Brain Tumors. 1995; 191-214.
  508. Loeffler JS, Shrieve DS, alexander E, Kooy HN, Tarbell NJ, Stieg PE, Wen PY, Black PMcL. Stereotactic radiotherapy for meningiomas. Alexander E, Kondzioloka D, Lindquist C, Loeffler JS, editors. Radiosurgery. 1995; 1:47-54.
  509. Wen PY, Fine HA, Loeffler JS, Black P. Malignant Gliomas. Samuels MA, Feske S, editors. Office Practice of Neurology. 1995; 836-844.
  510. Wen PY, Black PMcL. Introduction to Brain Tumors in Adults. Neurologic Clinics. 1995; 13:953-974.
  511. Swoboda K, Wen PY. Neurologic complications of bone marrow transplantation and graft versus host disease. Samuels MA, Feske S, editors. Office Practice of Neurology. 1995; 944-948.
  512. Schwarz MS, Loeffler JS, Black PMcL, Shrieve DC, Wne PY, Fine HA, Alexander E. Reoperation following radiosurgery of gliobastoma: impact on survival and neurologic statuts. Alexander E, Kondzioloka D, Lindquist C, Loeffler JS, editors. Radiosurgery. 1995; 141-157.
  513. Wen PY. Clinical Presentation and Diagnosis of Brain Tumors. Samuels MA, Feske S, editors. Office Practice of Neurology. 1995; 813-817.
  514. Non-metastatic complications of cancer. 1995.
  515. Initial management of gliomas including diagnosis and prognosis. 1995.
  516. Wen PY. General principles of management of patients with brain tumors. Samuels MA, Fesk S, editors. Office Practice of Neurology. 1995; 817-824.
  517. Wen PY, Schiff D, Hsu L. Uncommon brain tumors and intracranial cysts. Samuels MA, Feske S, editors. Office Practice of Neurology. 1995; 887-892.
  518. Wen PY. Neurologic Complications of Chemotherapy. Samuels MA, Feske S, editors. Office Practice of Neurology. 1995; 914-919.
  519. Hersh B, Dalmau J, Dan gond F, Geller E, Wen PY. Opsoclonus-myoclonus with anti-Hu antibody [letter]. Neurology. 1995; 45:1421.
  520. Black PM, Wen PY, editors. Brain Tumors in Adults. Neurologic Clinics. 1995.
  521. Moriarty TM, Loeffler JS, Black PMcL, Wen PY, Fine HA, Kooy HM, Alexander E. Stereotactic radiosurgery for the treatment of brain metastases: an update. Alexander E, Kondzioloka D, Lindquist C, Loeffler JS, editors. Radiosurgery. 1995; 83-91.
  522. Wen P, Locker J. A novel hepatocytic transcription factor that binds the alpha-fetoprotein promoter-linked coupling element. Mol Cell Biol. 1994 Oct; 14(10):6616-26. PMID: 7523856; PMCID: PMC359191.
  523. Hersh B, Dalmau J, Dangond F, Gultekin S, Geller E, Wen PY. Paraneoplastic opsoclonus-myoclonus associated with anti-Hu antibody. Neurology. 1994 Sep; 44(9):1754-5. PMID: 7936310.
    View in: PubMed
  524. Riese NE, Loeffler JS, Wen P, Alexander E, Black PM, Coleman CN. A phase I study of etanidazole and radiotherapy in malignant glioma. Int J Radiat Oncol Biol Phys. 1994 Jun 15; 29(3):617-20. PMID: 8005825.
    View in: PubMed
  525. Wen PY, Alexander E, Black PM, Fine HA, Riese N, Levin JM, Coleman CN, Loeffler JS. Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer. 1994 Jun 15; 73(12):3029-36. PMID: 8200000.
    View in: PubMed
  526. Wen PY, Alexander E, Loeffler JS. Stereotactic radiosurgery treats intracranial lesions. Diagn Imaging (San Franc). 1994 May; 16(5):76-80, 107. PMID: 10147089.
    View in: PubMed
  527. Epstein C, Lynch T, Shefner J, Wen P, Maxted D, Braman V, Ariniello P, Coral F, Ritz J. Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. Int J Cancer Suppl. 1994; 8:57-9. PMID: 7515030.
    View in: PubMed
  528. Riese NE, Rieker P, Wen P, Buswell L. A pilot study: Quality of Life in Pimary Brain Tumor Patients. Quality of Life Newsletter. 1994; 9:10.
  529. Non-metastatic complications of cancer. 1994.
  530. Epstein C, Lynch T, Shefner J, Wen P, Maxted D, Braman V, Arinello P, Coral F, Ritz J. Use of immunotoxin N901-blocked ricin in patients with small cell lung cancer. Int J Oncol. 1994; Supp 8:57-59.
  531. Management issues in brain tumor patients. 1994.
  532. Cross JC, Wen P, Rutter WJ. Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases. Proc Natl Acad Sci U S A. 1993 Sep 1; 90(17):8078-82. PMID: 8367466; PMCID: PMC47291.
  533. Wen P, Shanti I. Use of cerebral imaging in patients with headaches. Arch Intern Med. 1993 Jul 12; 153(13):1613-4. PMID: 8323425.
    View in: PubMed
  534. Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1993 Jun; 43(6):1111-4. PMID: 8170553.
    View in: PubMed
  535. Schiff D, Feske SK, Wen PY. Deceptively normal ventricular fluid in lymphomatous meningitis. Arch Intern Med. 1993 Feb 8; 153(3):389-90. PMID: 8427541.
    View in: PubMed
  536. Slivka A, Wen PY, Shea WM, Loeffler JS. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med. 1993 Feb; 94(2):216-9. PMID: 8381584.
    View in: PubMed
  537. Alexander E, Black PMcL, Wen PY, Fine H, Loeffler JS. Results of radiosurgery versus brachytherapy for malignant gliomas. DeSalles AAF, Goetsch SJ, editors, Stereotactic surgery and radiosurgery. 1993; 455-461.
  538. Non-CNS complications of brain tumors. 1993.
  539. Black PMcL, Loeffler JS, Alexander E, Tarbell N, Fine HA, Wen PY, Scott RM, Sallan S, Moore MR. Hemispheric Stroglial Neoplasms in Adults and Children. Black PMcL, LSchoene WC, Lampson LA, editors. Astrocytomas. 1993; 151-165.
  540. Paraneoplastic syndromes. 1993.
  541. Wen, P. Clinical Experience with Immunotherapy. Black PMcL, Schoene WC, Lampson LA, editors. Astrocytomas. 1993; 123-150.
  542. Wen P, Shanti I. Neuroimaging for headaches [letter]. Arch Int Med. 1993; 1613.
  543. Wen PY, Schiff D. Clinical Evaluation of Patients with Astrocytomas. Black, PMcL, Schoene WC, Lampson LA, editors. Astrocytomas. 1993; 26-36.
  544. Loeffler JS, Alexander E, Shea WM, Wen PY, Fine HA, Kooy HM, Black PM. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol. 1992 Sep; 10(9):1379-85. PMID: 1325539.
    View in: PubMed
  545. Wen P. Major histocompatibility antigens in murine tumors. J Neurosurg. 1992 Jun; 76(6):1048-50. PMID: 1588418.
    View in: PubMed
  546. Wen PY, Blanchard KL, Block CC, Loeffler JS, Davis DG, Lacroix LA, Antin JH. Development of Lhermitte's sign after bone marrow transplantation. Cancer. 1992 May 1; 69(9):2262-6. PMID: 1562971.
    View in: PubMed
  547. Sandson TA, Wen PY, LeMay M. Reversed cerebral asymmetry in women with breast cancer. Lancet. 1992 Feb 29; 339(8792):523-4. PMID: 1346881.
    View in: PubMed
  548. Lampson LA, Wen P, Roman VA, Morris JH, Sarid JA. Disseminating tumor cells and their interactions with leukocytes visualized in the brain. Cancer Res. 1992 Feb 15; 52(4):1018-25. PMID: 1737331.
    View in: PubMed
  549. Loeffler JS, Macklis RM, Wen PY, Fine HA, Alexander E, Coleman CN. Alternative and future strategies in the treatment of malignant gliomas. Sem Rad Oncol. 1992; 36:57-68.
  550. Wen PY, Lampson MA, Lampson LA. Effects of gamma-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy. J Neuroimmunol. 1992 Jan; 36(1):57-68. PMID: 1735769.
    View in: PubMed
  551. Non-surgical treatments of CNS malignancies. 1992.
  552. Coleman CN, Noll L, Riese N, Buswell L, Howes AE, Loeffler JS, Alexander E, Wen P, Harris JR, Kramer RA, et al. Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study. Int J Radiat Oncol Biol Phys. 1992; 22(3):577-80. PMID: 1531217.
    View in: PubMed
  553. Riese N, Coleman CN, Noll L, Buswell L, Loeffler J, Alexander E, Kooy H, Wen P, Harris JR, Howes A, Kramer R, Grisby P. A phpase 1 study of continuous infusion of etanidazole (SR2508) with brachytherapy. Int J Radiat Oncol Biol Phys. 1992; 22:577-580.
  554. Cancer Neurology. 1992.
  555. Wen P. MHC expression in murine tumors [letter]. J Neurosurg. 1992; 76:1048-9.
  556. Loeffler JS, Alexander E, Wen PY, Kooy HM, Fine HA, Black PM. Radiosurgery for brain metastases: 5 year experience at the Brigham and Women's Hospital. Lunsford LD, editor. Stereotactic Radiosurgery Update. 1992; 383-392.
  557. Dangond F, Lacomis D, Schwartz RB, Wen PY, Samuels MA. Acute disseminated encephalomyelitis progressing to hemorrhagic encephalitis. Neurology. 1991 Oct; 41(10):1697-8. PMID: 1922828.
    View in: PubMed
  558. Management of Brain Tumors. 1991.
  559. Schiff D, Wen PY. Parkinson's Disease: Anatomy, Pathology and Therapy (Streifler et al) [book review]. New Engl J Med. 1991; 324:1000.
  560. Loeffler JS, Alexander E, Kooy HM, Wen PY, Fine HA, Black PM. Stereotactic radiosurgery for brain metastases. DeVita VT, Hellman S, Rosenberg SA, editors. Cancer Principles and Practice of Oncology Updates. 1991; 5(2):1-12.
  561. Neurologic complications of cancer therapy. 1991.
  562. Wen P. Brain Tumors. Carskadon M, Rechtschaffen A, Richardson G, Roth G, Siegel J, editors. Encycolpedia of Sleep and Dreaming. 1991.
  563. Loeffler JS, Alexander E, Wen PY, Shea WM, Coleman CN, Kooy HM, Fine HA, Nedzi LA, Silver B, Riese NE, et al. Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J Natl Cancer Inst. 1990 Dec 19; 82(24):1918-21. PMID: 2250312.
    View in: PubMed
  564. Loeffler JS, Alexander E, Hochberg FH, Wen PY, Morris JH, Schoene WC, Siddon RL, Morse RH, Black PM. Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radiat Oncol Biol Phys. 1990 Dec; 19(6):1455-62. PMID: 2262370.
    View in: PubMed
  565. Kassis AI, Van den Abbeele AD, Wen PY, Baranowska-Kortylewicz J, Aaronson RA, DeSisto WC, Lampson LA, Black PM, Adelstein SJ. Specific uptake of the auger electron-emitting thymidine analogue 5-[123I/125I]iodo-2'-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans. Cancer Res. 1990 Aug 15; 50(16):5199-203. PMID: 2379179.
    View in: PubMed
  566. Wen P, Loeffler JS, Morris JH, Lampson LA. The effects of irradiation on major histocompatibility complex expression and lymphocytic infiltration in the normal rat brain and the 9L gliosarcoma brain tumor model. J Neuroimmunol. 1990 May; 27(2-3):239-44. PMID: 2332484.
    View in: PubMed
  567. Loeffler JS, Kooy HM, Wen PY, Fine HA, Cheng CW, Mannarino EG, Tsai JS, Alexander E. The treatment of recurrent brain metastases with stereotactic radiosurgery. J Clin Oncol. 1990 Apr; 8(4):576-82. PMID: 2179476.
    View in: PubMed
  568. Loeffler JS, Siddon RL, Wen PY, Nedzi LA, Alexander E. Stereotactic radiosurgery of the brain using a standard linear accelerator: a study of early and late effects. Radiother Oncol. 1990 Apr; 17(4):311-21. PMID: 2343148.
    View in: PubMed
  569. Wen P, Loeffler JS, Morris JM, Lampson LA. The effect of radiation on leukocytic infiltration and MHC expression in the rat brain and the 9L gliosarcoma brain tumor model. J. Neuroimmunology. 1990; 27:239-244.
  570. Antonucci TK, Wen P, Rutter WJ. Eukaryotic promoters drive gene expression in Escherichia coli. J Biol Chem. 1989 Oct 25; 264(30):17656-9. PMID: 2681182.
    View in: PubMed
  571. Wen P. Interferon therapy for recurrent gliomas. J Neurosurg. 1989 Apr; 70(4):660-1. PMID: 2466969.
    View in: PubMed
  572. Wen P. Interferon Therapy for Malignant Gliomas [letter]. J. Neurosurg. 1989; 70:660.
  573. Wen P. Nifedipine for Epilepsy? [letter]. British Medical Journal. 1988; 296:1069.
  574. Wen HL, Ho WK, Wen PY. Comparison of the effectiveness of different opioid peptides in suppressing heroin withdrawal. Eur J Pharmacol. 1984 Apr 20; 100(2):155-62. PMID: 6329773.
    View in: PubMed
  575. Wen P. [letter]. British Medical Journal. 1984; 287:1983.
  576. Gibb WRG, Wen P . Current practice of Diagnostic Lumbar Puncture. British Medical Journal. 1984; 289:530.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For demographic and contact information changes only, HMS/HSDM faculty should contact Human Resources at human_resourceshms.harvard.edu.
Wen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_